The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases

Luca Antonioli, Corrado Blandizzi, Pál Pacher, and György Haskó

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (L.A., C.B.); Laboratory of Cardiovascular Physiology and Tissue Injury, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (P.P.); and Department of Anesthesiology, Columbia University, New York, New York (G.H.)

Abstract—Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs.

I. Introduction to the Purinergic System
The purinergic system is an intricate jigsaw puzzle of mediators, receptors, transporters, and synthetic and catabolic enzymes to which scientific research continues to add new pieces on a daily basis (Antonioli et al., 2013b; Burnstock, 2016, 2018).

Address correspondence to: Dr. György Haskó, Department of Anesthesiology, Columbia University, 622 W. 168th St., P&S Box 46, New York, NY 10032. E-mail: gh2503@cumc.columbia.edu

This work was supported by National Institutes of Health National Institute of General Medical Sciences Grant R01GM066189 and National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK113790 (both to G.H.).

Disclosure: G.H. has stock in Purine Pharmaceuticals, Inc.

https://doi.org/10.1124/pr.117.014878.
Purinergic signaling is initiated by the release of nucleotides and nucleosides into the extracellular space through volume regulated anion channels, maxi-anion channels, transporters, connexins, and pannexins (Taruno, 2018), as well as through exocytotic pathways and membrane damage (Fig. 1) (Antonioli et al., 2013b). Following their release into the extracellular space, the nucleotides and nucleosides bind to specific receptors located on the surface of the target cell membrane. The cellular signals triggered by nucleotides, including ATP, ADP, UTP, UDP, and UDP-glucose, are mediated by the engagement of P2 receptor subtypes, which are classified into ionotropic P2X (P2X<sub>1-7</sub>) and metabotropic P2Y (P2Y<sub>1,2,4,6,11-14</sub>) receptors (Fig. 1) (Antonioli et al., 2013b).

P2X receptors have a trimeric topology with two transmembrane domains, gating primarily Na<sup>+</sup>, K<sup>+</sup>, and Ca<sup>2+</sup> and, occasionally Cl<sup>-</sup> (Pawson et al., 2014). Activation of the G<sub>i1</sub>-coupled P2Y<sub>1,2,4,6</sub> and P2Y<sub>11</sub> receptors leads to the stimulation of phospholipase C, which initiates the production of inositol-(1,4,5)-trisphosphate and diacylglycerol (Franke et al., 2006). Inositol-(1,4,5)-trisphosphate increases intracellular Ca<sup>2+</sup> levels and diacylglycerol stimulates protein kinase C (Franke et al., 2006). In addition, P2Y<sub>11</sub> receptor activation can stimulate whereas P2Y<sub>12,13</sub> receptor activation can inhibit adenylate cyclase (Franke et al., 2006).

The most important extracellular nucleosides are adenosine and inosine, and they signal through G protein-coupled P1 or adenosine receptors. They are classified into A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> (Antonioli et al., 2019) (Fig. 1). A<sub>1</sub> and A<sub>2A</sub> receptors are coupled to G<sub>i</sub>, G<sub>q</sub>, and G<sub>s</sub> proteins. A<sub>2A</sub> and A<sub>2B</sub> receptors activate adenylate cyclase via G<sub>i</sub> or G<sub>s</sub> (Antonioli et al., 2019). The engagement of A<sub>2B</sub> receptors can also activate phospholipase C via G<sub>i</sub> (Antonioli et al., 2013a, 2019).

Purinergic signaling through receptors is regulated by the availability of extracellular purines and tightly controlled by nucleotidases/phosphatases and kinases. In this regard, the cell surface ecto-enzyme axis, comprising the phosphatases CD39 and CD73, is the major mediator of the degradation of extracellular ATP, ADP, and AMP into adenosine (Antonioli et al., 2013c) (Fig. 1). In addition, the CD38-CD203a (ectonucleotide pyrophosphatase/phosphodiesterase 3) enzyme axis on the cell surface, which operates independently or in synergy with the CD39/CD73 pathway, also contributes to the metabolism of extracellular purines (Morra et al., 1998; Bahri et al., 2012). In particular, CD38 catalyzes the synthesis of cyclic ADP-ribose from nicotinamide adenine dinucleotide (NAD<sup>+</sup>), and mediates the hydrolysis of cyclic ADP-ribose to ADP-ribose (Quarona et al., 2013; Hasko et al., 2018) (Fig. 1). The pyrophosphatase/phosphodiesterase CD203a is capable of hydrolyzing both NAD<sup>+</sup>, ADP-ribose and also ATP to produce AMP, which can then be degraded into adenosine by CD73 (Quarona et al., 2013; Horenstein et al., 2016; Hasko et al., 2018) (Fig. 1).

Most cell types in the body are endowed with nucleoside transporters, which can transport purines across the cell membrane from the intra- to the extracellular space and vice versa, thus contributing to both the initiation and termination of purinergic signaling (Fredholm et al., 2011; Pastor-Anglada et al., 2018) (Fig. 1). Based on their molecular and functional characteristics, nucleoside transporters are classified into 1) equilibrative nucleoside transporters (ENTs; ENT1, ENT2, ENT3, and ENT4), which carry nucleosides across cell membranes along their concentration gradients (Young, 2016; Boswell-Casteel and Hays, 2017), and 2) concentrative nucleoside transporters (CNTs; CNT1, CNT2, and CNT3), which mediate the cellular uptake of nucleosides against their concentration gradient (Young, 2016). Once the cell takes up adenosine, it is quickly phosphorylated to AMP via adenosine kinase (Antonioli et al., 2010a; Camici et al., 2018). In parallel, the metabolizing enzyme adenosine deaminase converts adenosine into inosine both intra- and extracellularly (Fig. 1) (Antonioli et al., 2012). Intracellular inosine is ultimately converted into the stable end product uric acid by xanthine oxidase (Fig. 1).

Purinergic pathways have long been known to contribute to homeostasis in healthy organisms through regulating several organ systems, which include the cardiovascular, renal, gastrointestinal, and central nervous systems (Antonioli et al., 2013b; Bele and Fabbretti, 2015; Burnstock, 2017). It has also been

**ABBREVIATIONS:** ADA, adenosine deaminase; SCH 442416, 5-amino-7-(3-(4-methoxyphenyl)propyl)-2-(2-furyl)pyrazolo[43-e]-1,2,4-triazolo[1,5-c]pyrimidine; AZD9056, N-1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; BAL, bronchoalveolar lavage; BAY 60-6583, 2-(6-amino-5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridiny1)thioacetamide; CD38, cyclic ADP ribose hydrolase; CD93, ectonucleoside triphosphate diphosphohydrolase 1; CD73, ecto-5’-nucleotidase; CNT, concentrative nucleoside transporter; COPD, chronic obstructive pulmonary disease; DC, dendritic cell; DSS, dextran sulfate sodium; EAE, experimental autoimmune encephalomyelitis; EAMG, experimental autoimmune myasthenia gravis; EAU, experimental autoimmune uveitis; ENT, equilibrative nucleoside transporter; IBD, inflammatory bowel disease; IB-MECA, 1-deoxy-1-β-[3-(iodophenyl)methyl]aminol-9H-purin-9-yl-N-methyl-3-amino-1-β-[3-chloro-2-(3-methyl-5-oxazolyl)methyl]phenoxy)methyl]amino)-9H-purin-9-yl-1,3-dideoxy-N-methyl; IFN, interferon; IMID, immune-mediated inflammatory disease; KO, knockout; MG, myasthenia gravis; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NAD<sup>+</sup>, nicotinamide adenine dinucleotide; NECA, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-3-amino-1-β-[3-chloro-2-(3-methyl-5-oxazolyl)methyl]phenoxy)methyl]amino)-9H-purin-9-yl-1,3-dideoxy-N-methyl; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NK, natural killer; OVA, ovalbumin; oxATP, oxidized ATP; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNBS, trinitrobenzenesulfonic acid; TNF, tumor necrosis factor.
known for almost a century that purinergic signaling is especially important as a regulator of organ function during and following the disruption of homeostasis, which is due to the fact that extracellular purines accumulate in response to homeostasis-disrupting factors, such as tissue injury and changes in the extracellular milieu (e.g., hypoxia, acidosis, ion balance disturbances, and alterations in hormones and neurotransmitters). In the last few decades, the immune system has emerged as a major target of purinergic signaling in both homeostasis and disease. In the present review we will first discuss the role of the purinergic system in regulating immune cell function in homeostasis. Building on this understanding of how purinergic signaling regulates immune function in a healthy organ system, we will then provide an overview about the role of purinergic signaling in sustaining and or controlling immune-mediated inflammatory diseases (IMIDs) and the underlying immune and inflammatory pathways. Finally, we will highlight the possible therapeutic applications of drugs acting on the purinergic machinery in managing patients suffering from IMIDs.

II. Pharmacological Modulation of Purinergic Pathways

Growing efforts are being focused on the design and synthesis of novel pharmacological entities comprising selective agonists and antagonists for ATP and adenosine receptor subtypes (see Table 1), as well as on tools able to regulate the endogenous levels of purines through interfering with the function of synthetic/catabolic enzymes and transporters (see Table 2).

Direct receptor-targeting efforts comprise the development of competitive agonists or antagonists that are able to interact, with increasing selectivity, with the main binding sites of the receptors (orthosteric drugs). Drug design is aided by the ever increasing number of resolved crystal structures of the various purinergic receptors, enzymes, and transporters. Biased agonism is an emerging concept in the pharmacology of G-protein-coupled receptor signaling, which provides for the possibility that a given ligand is able to preferentially activate one (or some) of the possible signaling pathways (Pupo et al., 2016). This is an intriguing point, since if different processes downstream of the same receptor are involved in a pathologic condition, biased ligands would have the potential to selectively activate the therapeutically relevant pathway sparing other signaling, thus limiting adverse events. This is a relevant aspect especially in the pharmacology of the purinergic system, due to the wide distribution throughout the body of P1 and P2 receptors and their involvement in modulating several physiologic functions. In addition, there are further questions that need to be answered during the drug design process. For example, do potential antagonists operate as neutral antagonists or are they also inverse agonists? Would it be possible to develop peripheral or central nervous system-penetrable agonists/antagonists?

In addition, as the wide distribution of purinergic receptors throughout the body increases the risk of
adverse effects after orthosteric agonist administration, the development of allosteric modulators of purinergic receptors has represented another area of active research. By binding to sites different from the primary one for endogenous ligands, allosteric ligands act by modulating receptor conformation only in the presence of the endogenous agonist; that is, at sites of tissue distress (Antonioli et al., 2011, 2010b, 2014; Coddou et al., 2011; Goblyos and Ijzerman, 2011; Muller, 2015; De Marchi et al., 2016). The usefulness of this approach is underlined by studies showing that allosteric antagonists for P2X3, P2X4, and P2X7 had beneficial effects in preclinical models of joint inflammation and asthma (Ford and Undem, 2013).

In addition to the direct receptor-targeting ligands, increasing efforts have been focused on identifying novel pharmacological agents able to modulate the extracellular levels of endogenous purines through targeting catabolic enzymes, nucleoside transporters, and other release mechanisms (see Table 2). In addition, a number of anti-inflammatory agents currently used to treat IMIDs, such as cyclosporine (Neoral, Sandimmune, Gengraf), salicylates (aspirin), methotrexate (Trexall, Rasuvo, Otrexup), sulfasalazine (Azulfidine, Sulfazine, Azulfidine EN-tabs), and the novel JAK-STAT inhibitor tofacitinib (Xeljanz, Xeljanz XR) have been shown to exert their beneficial effects by increasing extracellular adenosine levels (Morabito et al., 1998; Cronstein et al., 1999; Capecchi et al., 2005; Cronstein, 2006b; Koizumi et al., 2015).

MicroRNAs (miRNAs) are small noncoding RNAs that are approximately 20–25 nucleotides in length, which regulate the expression of multiple target genes through sequence-specific hybridization to the 3’-untranslated region of messenger RNAs (Christopher et al., 2016). A number of pharmacological tools have been developed to target miRNA pathways (van Rooij and Kauppinen, 2014). Ferrari et al. (2016) have reviewed the available data on the modulatory role of miRNAs in regulating the expression of molecular components of the purinergic network as summarized in Table 3. For these reasons, therapies aimed at specifically modulating purinergic miRNAs could hopefully be introduced to treat IMIDs (Ferrari et al., 2016). At present, the main challenges, which remain to be addressed for developing miRNA-based therapeutics, are efficacious delivery to target tissues and cells, potential off-target effects and safety (Garzon et al., 2010).

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Signaling</th>
<th>Agonists</th>
<th>Antagonists</th>
<th>Allosteric modulators</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2 receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2X1</td>
<td>ligand-gated ion channel</td>
<td>2-MeSATP, L-β,γ-meATP, α-β-meATP, BzATP, HT-AMP, PAPET-ATP, Ap5A, CTP</td>
<td>TNP-ATP, Ip4l, NF023, NF449, NF279, PPNDs, Ro 0437626, IsoPPADS, MRS2159, phenol red, suramin</td>
<td>—</td>
</tr>
<tr>
<td>P2X2</td>
<td>ligand-gated ion channel</td>
<td>—</td>
<td>NF770, NF778, NF 279, PSB-10211, PPADS, RB-2, suramin, TNP-ATP</td>
<td>—</td>
</tr>
<tr>
<td>P2X3</td>
<td>ligand-gated ion channel</td>
<td>2-MeSATP, α-β-meATP, BzATP, D-β,γ-meATP, 2-MeSATP, HT-AMP, PAPET-ATP, Ap5A</td>
<td>TNP-ATP, A317491, AF-906, AF-219, RO3, NF110, spinorphin</td>
<td>—</td>
</tr>
<tr>
<td>P2X4</td>
<td>ligand-gated ion channel</td>
<td>—</td>
<td>BX-430, BBG, phenolphtalein, TNP-ATP 5-BDBD, PSB-12062, paroxetin</td>
<td>Ivermectin (positive)</td>
</tr>
<tr>
<td>P2X5</td>
<td>ligand-gated ion channel</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>P2X6</td>
<td>ligand-gated ion channel</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>P2X7</td>
<td>ligand-gated ion channel</td>
<td>—</td>
<td>Brilliant Blue G, A804598, A839977, decavanadate, KN62, KN-04, BBG, oxidized-ATP, A740003, A438079, AZ10606110</td>
<td>AZ10606120 (negative), GW791343 (positive), GW791343 (negative), chelerythrine (negative), AZ11645379 (negative) KN62 (negative) Ivermectin (positive)</td>
</tr>
<tr>
<td>P2Y1</td>
<td>Gq</td>
<td>2-CI-ADP(α-BH3), 2-MeSADP, ADPβS, MRS 2365</td>
<td>MRS2500, MRS2279, MRS2179, PIT</td>
<td>2,2’-pyridilisatoxylate (negative), BMS compound 16 (negative)</td>
</tr>
<tr>
<td>P2Y2</td>
<td>Gq</td>
<td>UTPgS, Ap4A, 2-thioU TP, MRS2698, MRS2768, PSB1114</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>P2Y4</td>
<td>Gq</td>
<td>MRS4062, MRS2927, (N)methanocarba UTP, UTPgS</td>
<td>PPADS, reactive blue-2, ATP</td>
<td>—</td>
</tr>
<tr>
<td>P2Y6</td>
<td>Gq</td>
<td>UDP, 3-phenacyl UDP PSB0474, MRS2693, MRS2957</td>
<td>MRS2578, MRS2567</td>
<td>—</td>
</tr>
<tr>
<td>P2Y11</td>
<td>Gq</td>
<td>ATPgS, NF546, AR-C67085, NAD+</td>
<td>NF157, NF340</td>
<td>—</td>
</tr>
<tr>
<td>P2Y12</td>
<td>Gq</td>
<td>2-MeSADP, ADPβS</td>
<td>PSB-0739, AR-C 66096, ATP, AZD1283, ARL66096, cangrelor, Ap4a, ticlopidine</td>
<td>MRS2211, MRS2603, cangrelor, Ap4a</td>
</tr>
<tr>
<td>P2Y13</td>
<td>Gq</td>
<td>2-MeSADP, 2-MeSATP, MRS2905, αβ methilen 2-thioUTP, 2-thioUDP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2Y14</td>
<td>Gq</td>
<td>MRS2905, αβ methilen 2-thioUTP, 2-thioUDP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Receptor</th>
<th>Signaling</th>
<th>Agents</th>
<th>Antagonists</th>
<th>Allotrophic modulators</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1 receptors</td>
<td>( \mathcal{P}_1 ) ( \mathcal{G}_0 )</td>
<td>R-PIA, GW493838, CHA, CPA, CCPA, TCPA, 2'-Me-CCPA, GR79236, selodenoan, capadenosan, tecadeanon, NS0667</td>
<td>PDB1723 (positive)</td>
<td>—</td>
</tr>
<tr>
<td>A(\Delta)G</td>
<td>( \mathcal{A}_\Delta ) ( \mathcal{G}_0 )</td>
<td>CGS21880, ATL-313, ATL-146e, UK-42957, compound 4g, selodenoan, capadenosan, regadenosan, NECa, Bay 60-6853</td>
<td>KV8092, CSX-MS-2, SY115, BIBO104, ST-1553, SCH442416, ZM413855, SCH58261, preladenant</td>
<td>—</td>
</tr>
<tr>
<td>A(\Delta)G</td>
<td>( \mathcal{A}_\Delta ) ( \mathcal{G}_0 )</td>
<td>CF-101, CF-102, CF-502, CO 6803,93, MRS155, IB-MECA, MRS5698</td>
<td>KP2777, PS-10, PS-11, MREFS-2008-MR2201, MRS2201, MRS2206</td>
<td>LUF6000 (positive), LUF6006 (negative)</td>
</tr>
</tbody>
</table>

Preclinical studies support the use of agents targeting the purinergic system for treating immune and/or inflammatory disorders (see Table 4). In the wake of these preclinical findings, several ligands acting on various purinergic targets have been or are being tested in clinical trials (see Table 5).

...
### III. Purinergic Signaling in Immune Cells Contributes to Homeostasis

Emerging evidence indicates that purines contribute to immune homeostasis (Hasko and Cronstein, 2004; Trautmann, 2009; Junger, 2011; Csóka et al., 2012b, 2015a; Longhi et al., 2013; Burnstock and Boeynaems, 2014; Sevigny et al., 2015; Cekic and Linden, 2016; Csóka et al., 2012a; Hasko et al., 2018). Under resting or physiologic conditions, immune cells release low levels of ATP, creating a “purinergic halo” in their immediate environment (Trautmann, 2009). Such an ATP “halo” is a low-intensity signal addressed to the closest neighboring cells, which makes these neighboring “target” cells aware of the ATP-emitting cells (Trautmann, 2009). Responses to low ATP concentrations are mediated by high affinity receptors such as P2X1, P2X3, P2Y2, and P2Y13 (EC50 < 1 μM) or by intermediate affinity receptors comprising P2X2, P2X4, P2X5, P2X6, P2Y1, P2Y4, and P2Y11 (EC50 1–20 μM) (Trautmann, 2009) (Table 6).

P2 receptors are involved in regulating homeostasis, as revealed by the alterations of cell and tissue functions in “unstressed” P2-deficient mice. For example, both P2Y1 or P2Y12 KO mice exhibit a defect in platelet aggregation and show increased resistance to thromboembolism (Foster et al., 2001; Léon et al., 1999). P2Y2 KO mice are characterized by a decrease in vascular cell adhesion molecule 1 expression on endothelial cells (Qian et al., 2016).

The degradation of the physiologically released ATP creates an “adenosine halo,” which is also important for maintaining immune homeostasis. For example, A2A receptors are important for T cell development and

### TABLE 2

<table>
<thead>
<tr>
<th>Commercially available blockers for purinergic enzymes and transporters</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD39</td>
</tr>
<tr>
<td>CD73</td>
</tr>
<tr>
<td>CD38</td>
</tr>
<tr>
<td>Nucleoside transporters</td>
</tr>
<tr>
<td>Adenosine deaminase</td>
</tr>
</tbody>
</table>

### TABLE 3

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Target in the Purinergic Pathway</th>
<th>Biologic Effect</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2X7</td>
<td>miR-150</td>
<td>Inhibition</td>
<td>Huang et al. (2013)</td>
</tr>
<tr>
<td></td>
<td>miR-186</td>
<td>Inhibition</td>
<td>Zhou et al. (2008)</td>
</tr>
<tr>
<td></td>
<td>miR-216b</td>
<td>Inhibition</td>
<td>Zheng et al. (2014)</td>
</tr>
<tr>
<td></td>
<td>miR-22</td>
<td>Inhibition</td>
<td>Jimenez-Mateos et al. (2015)</td>
</tr>
<tr>
<td></td>
<td>miR-21</td>
<td>Inhibition</td>
<td>Boldrini et al. (2015)</td>
</tr>
<tr>
<td></td>
<td>miR-125b</td>
<td>Stimulation</td>
<td>Parisi et al. (2016)</td>
</tr>
<tr>
<td>CD39</td>
<td>miR-155</td>
<td>Stimulation</td>
<td>Liu et al. (2015)</td>
</tr>
<tr>
<td></td>
<td>miR-422a</td>
<td>Inhibition</td>
<td>Bonnin et al. (2016)</td>
</tr>
<tr>
<td></td>
<td>miR-30 family</td>
<td>Inhibition</td>
<td>Xie et al. (2017)</td>
</tr>
<tr>
<td></td>
<td>miR-340</td>
<td>Inhibition</td>
<td>Wang et al. (2018b)</td>
</tr>
<tr>
<td></td>
<td>miR-187</td>
<td>Inhibition</td>
<td>Zhang et al. (2016)</td>
</tr>
<tr>
<td></td>
<td>miR-195b</td>
<td>Inhibition</td>
<td>Ikeda et al. (2012)</td>
</tr>
<tr>
<td></td>
<td>miR-214</td>
<td>Inhibition</td>
<td>Zhao et al. (2015)</td>
</tr>
<tr>
<td></td>
<td>miR-21</td>
<td>Stimulation</td>
<td>Villar-Menendez et al. (2014)</td>
</tr>
<tr>
<td>A2A</td>
<td>miR-54</td>
<td>Inhibition</td>
<td>Heyn et al. (2012)</td>
</tr>
<tr>
<td></td>
<td>miR-27b</td>
<td>Stimulation</td>
<td>Heyn et al. (2012)</td>
</tr>
<tr>
<td></td>
<td>miR-128a</td>
<td>Inhibition</td>
<td>Kolachala et al. (2010)</td>
</tr>
<tr>
<td></td>
<td>miR-128b</td>
<td>Stimulation</td>
<td>Kolachala et al. (2010)</td>
</tr>
<tr>
<td>ADA 2</td>
<td>miR-14-3p</td>
<td>Inhibition</td>
<td>Fulzele et al. (2015)</td>
</tr>
<tr>
<td>Experimental Model</td>
<td>Animal</td>
<td>Molecular Target</td>
<td>Ligand</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>--------</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>C57BL/6 mice</td>
<td>P2X7</td>
<td>aATP (5 or 10 mg/kg/day), Brilliant Blue G (5 or 10 mg/kg/day)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6 mice</td>
<td>P2Y12</td>
<td>Clopidogrel (5, 15, 50 mg/kg/day), Ticagrelor (30 mg/kg/day)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6 mice</td>
<td>A2A</td>
<td>SCH58261 (2 mg/kg/day)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6 mice</td>
<td>A2A</td>
<td>CGS21680 (0.01 or 0.05 mg/kg/day)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6 mice</td>
<td>A2B</td>
<td>CVT-6883 (0.3, 1, 3 mg/kg/day), MRS-1754 (1 mg/kg/day)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>Female C57BL/6 (B6) mice</td>
<td>P2X7</td>
<td>OATP-iP injection of 3 days</td>
</tr>
<tr>
<td></td>
<td>Female C57BL/6 (B6) mice</td>
<td>Adenosine receptors</td>
<td>Adenosine receptor agonists (NECA, IP injection of 100 ng/mouse)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6 mice</td>
<td>A2A</td>
<td>CGS 21680 0.5 mg/kg given i.p. once a day for 3 days</td>
</tr>
<tr>
<td>Experimental Model</td>
<td>Animal</td>
<td>Molecular Target</td>
<td>Ligand</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>C57BL/6 mice</td>
<td>A3</td>
<td>CF101 10 μg/kg p.o., twice daily for 19 days</td>
<td>Improvement of uveitis clinical scores, amelioration of the pathologic manifestations of the disease and reduction of antigen-specific proliferation and cytokine production of autoreactive T cells</td>
</tr>
<tr>
<td>Female C57BL/6 (B6) mice</td>
<td>Endogenous adenosine</td>
<td>ADA 5U/mouse given i.p. for 22 days</td>
<td>Suppression of the course of EAU when given 8–14 days post-immunization and augmentation when given either before or after this period</td>
</tr>
<tr>
<td>Myasthenia gravis Immunization with AChR R97-116 peptide</td>
<td>Female Lewis rats</td>
<td>A2A</td>
<td>CGS21680 0.5 mg/kg i.p. every 3 days for 29 days post EAMG induction</td>
</tr>
<tr>
<td>Rheumatoid arthritis Freund's adjuvant induced arthritis</td>
<td>DBA/1J mice</td>
<td>P2X7</td>
<td>Suramin (30 mg/kg), A-438079 (5 mg/kg)</td>
</tr>
<tr>
<td>Collagen-induced arthritis</td>
<td>C57BL/6 mice</td>
<td>A2A (pro-drug)</td>
<td>2-(cyclohexylthylthio) adenosine 5'-monophosphate (0.5 mg/kg/min)</td>
</tr>
<tr>
<td>Freund's adjuvant-induced arthritis</td>
<td>Lewis rats</td>
<td>A3</td>
<td>1-(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol (also named CF 502) (1, 10, and 100 μg/kg)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Experimental Model</th>
<th>Animal</th>
<th>Molecular Target</th>
<th>Ligand</th>
<th>Pharmacological Effect</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scleroderma&lt;br&gt;Bleomycin-induced fibrosis</td>
<td>Male C57BL/6 mice</td>
<td>A2A</td>
<td>ZM241385 (50 mg/kg i.p. twice per day)</td>
<td>Attenuation of bleomycin-induced dermal fibrosis (reduced punch biopsy skin thickness, lower skinfold thickness)</td>
<td>Chan et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Tcf/Lef:H2B-GFP mice</td>
<td>A2A</td>
<td>KW6002 (10 mg/kg once per day i.p)</td>
<td>Reduction of skin thickness, skinfold thickness, breaking tension, dermal hydroxyproline content, myofibroblast accumulation, and collagen alignment in bleomycin-induced dermal fibrosis</td>
<td>Zhang et al. (2017a)</td>
</tr>
<tr>
<td></td>
<td>C57BL/6J mice and TSK1 mice</td>
<td>A2B</td>
<td>C57BL/6J mice: GS-6201 (p.o for 15 days) TSK1 mice: GS-6201 (p.o for 30 days)</td>
<td>In C57BL/6J mice: reduction of dermal fibrosis and reduction of extracellular matrix molecule fibronectin and decreased number of alternatively activated macrophages. In TSK1 mice: reduction of dermal fibrosis at the hyperdermal layer and reduction in hyperdermal layer thickness. Reduction of IL-6 and MCP-1 in the skin</td>
<td>Karmouty-Quintana et al. (2018)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>12-Otetradecanoylphorbol-13-acetate&lt;br&gt;Swiss CD-1</td>
<td>A2A</td>
<td>CGS-21680 (5 µg per site)</td>
<td>Reduction of epidermal hyperplasia and promotion of collagen synthesis. Normalization of epidermal structure and enhancement of fibroblast proliferation in the dermis. Reduction of chemotactic mediator expression and NFκB inhibition</td>
<td>Arasa et al. (2014)</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>MRL/pr mice</td>
<td>A2A</td>
<td>CGS-21680 (0.4 mg/kg per day, i.p. for 8 wk)</td>
<td>Reduction in proteinuria, blood urea, and creatinine as well as improvement in renal histology. Reduction of renal macrophage and T-cell infiltration. Reduction of MCP-1, IFN-γ and MHC-II expression. Reduction of serum anti-dsDNA and renal immune complex deposition. Inhibition of NFκB activation and suppression of IFN-γ, MCP-1, and MHC-II expression in splenocytes</td>
<td>Zhang et al. (2011)</td>
</tr>
<tr>
<td>Experimental Model</td>
<td>Animal</td>
<td>Molecular Target</td>
<td>Ligand</td>
<td>Pharmacological Effect</td>
<td>References</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>----------------------------</td>
<td>------------------</td>
<td>-------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>Male WKY rats</td>
<td>P2X&lt;sub&gt;7&lt;/sub&gt;</td>
<td>A-438079 (300 μmol/kg i.p. injection twice daily for 7 days)</td>
<td>Reduction in fibrinoid necrosis, Reduction in proteinuria, Reduction in glomerular macrophage infiltration</td>
<td>Taylor et al. (2009)</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>Male WKY rats</td>
<td>P2X&lt;sub&gt;7&lt;/sub&gt;</td>
<td>brilliant blue G (45.5 mg/kg i.p. injection every 48 h for 8 wk)</td>
<td>Reduction of NLRP3/ASC/caspase 1 assembly, reduction of interleukin-1β release, Reduction in the severity of nephritis and circulating anti-dsDNA antibodies, Reduction of the serum levels of IL-1β and IL-17 and in the Th17:Treg cell ratio</td>
<td>Zhao et al. (2013)</td>
</tr>
<tr>
<td>Genetic model</td>
<td>MRL/&lt;i&gt;lpr&lt;/i&gt; mice</td>
<td>P2X&lt;sub&gt;7&lt;/sub&gt;</td>
<td>A2A CGS 21680 1.5 mg/kg i.p. twice a day for 5 days</td>
<td>Reduction of damage to the kidneys, Suppression of the glomerular expression of the MDC/CCL22 chemokine and down-regulation of MIP-1α/CCL3, RANTES/CCL5, MIP-1β/CCL4, and MCP-1/CCL2 chemokines, Increase of anti-inflammatory cytokines, IL-4 and IL-10</td>
<td>Garcia et al. (2008)</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>C57/Bl6 mice</td>
<td>P2X&lt;sub&gt;7&lt;/sub&gt;</td>
<td>KN62 (1 μM by mouth 30 min before each cigarette smoke exposure on days 1–3)</td>
<td>Prevention of the lung parenchyma destruction</td>
<td>Lucattelli et al. (2011)</td>
</tr>
<tr>
<td>Asthma</td>
<td>Balb&lt;sup&gt;c&lt;/sup&gt; and C57BL/6 mice</td>
<td>P2X&lt;sub&gt;4&lt;/sub&gt;</td>
<td>5-BBD (80 μl 100 μM, intratracheally before each of the three consecutive OVA-aerosol challenges)</td>
<td>Reduction of bronchoalveolar lavage fluid eosinophilia, peribronchial inflammation, Th2 cytokine production and bronchial hyperresponsiveness</td>
<td>Zech et al. (2016)</td>
</tr>
<tr>
<td></td>
<td>Balb&lt;sup&gt;c&lt;/sup&gt; and C57BL/6 mice</td>
<td>P2X&lt;sub&gt;7&lt;/sub&gt;</td>
<td>KN62 (10 μM, intratracheally before allergen challenge)</td>
<td>Reduction of airway eosinophilia, goblet cell hyperplasia, and bronchial hyperresponsiveness to methacholine</td>
<td>Muller et al. (2011)</td>
</tr>
<tr>
<td></td>
<td>Balb&lt;sup&gt;c&lt;/sup&gt; and C57BL/6 mice</td>
<td>P2Y&lt;sub&gt;1&lt;/sub&gt;</td>
<td>MRS2179: 30 mg/kg, MRS2500: 3 mg/kg administered intravenously 20 min before the start of allergen challenge</td>
<td>Reduction in allergic airway inflammation</td>
<td>Amison et al. (2015)</td>
</tr>
<tr>
<td></td>
<td>Female BALB/c mice</td>
<td>A&lt;sub&gt;2A&lt;/sub&gt;</td>
<td>CGS-21680 (10 or 100 μg/kg intranasally, half an hour before and 3 h after the challenge)</td>
<td>Inhibition of bronchoalveolar lavage fluid inflammatory cell influx</td>
<td>Bonnes et al. (2006)</td>
</tr>
<tr>
<td>Experimental Model</td>
<td>Animal</td>
<td>Molecular Target</td>
<td>Ligand</td>
<td>Pharmacological Effect</td>
<td>References</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>--------------------------------</td>
<td>------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Genetical model</td>
<td>ADA-deficient mice</td>
<td>A2B</td>
<td>CVT-6883 (1 mg/kg i.p. for 14 days)</td>
<td>No effect on OVA-induced bronchoconstriction</td>
<td>Sun et al. (2006)</td>
</tr>
<tr>
<td>Inflammatory bowel diseases</td>
<td></td>
<td></td>
<td></td>
<td>Reduction of immune cell number in the BAL fluid, Decreased production of pro-inflammatory cytokines and chemokines</td>
<td></td>
</tr>
<tr>
<td>Trinitrobenzene sulfonic acid</td>
<td>Wistar rats</td>
<td>P2X7</td>
<td>A740003 (16 mg/kg/day), Brilliant Blue G (40 mg/kg/day)</td>
<td>Amelioration of clinical and histologic scores, Reduction of macrophage and T-cell tissue infiltration, Reduction of tissue apoptosis</td>
<td>Marques et al. (2014)</td>
</tr>
<tr>
<td>Spontaneous ileitis</td>
<td>SAMP1/YitFc mouse</td>
<td>A2A</td>
<td>ATL-146e (0.1 μg · kg⁻¹ · min⁻¹)</td>
<td>Decrease of the chronic inflammatory index and villus distortion index, Reduction of NF-kappa B and MAP kinase activation</td>
<td>Odashima et al. (2005)</td>
</tr>
<tr>
<td>Oxazolone</td>
<td>Sprague-Dawley rats</td>
<td>A2A</td>
<td>PSB-0777 (0.4 mg/kg/day)</td>
<td>Amelioration of microscopic damage score, Reduction of tissue TNF and oxidative stress</td>
<td>Antonioli et al. (2018a)</td>
</tr>
<tr>
<td>Sodium dextran sulfate</td>
<td>NMRI mice</td>
<td>A2A</td>
<td>CGS 21680 (0.5 mg/kg/day)</td>
<td>CGS 21680 was ineffective in ameliorating DSS-induced colitis in mice</td>
<td>Selmeczy et al. (2007)</td>
</tr>
<tr>
<td>C57BL/6 mice</td>
<td>A2B</td>
<td>ATL-801 (10 mg/kg/day)</td>
<td>Reduction of clinical symptoms, histologic scores, IL-6 levels and proliferation indices, Suppression of the inflammatory infiltrate into colonic mucosa and decrease of epithelial hyperplasia</td>
<td>Kolachala et al. (2009a)</td>
<td></td>
</tr>
<tr>
<td>C57BL/6 mice</td>
<td>A2B</td>
<td>PSB1115 (1 mg/kg/day)</td>
<td>Increase in severity of DSS colitis</td>
<td></td>
<td>Frick et al. (2009)</td>
</tr>
<tr>
<td>BALB/c mice</td>
<td>A3</td>
<td>IB MECA (1 or 3 mg/kg/day b.i.d.)</td>
<td>Amelioration of clinical signs of colitis, Reduction of tissue IL-1, IL-6, IL-12 MIP-1, MIP-2, MPO, and MDA levels</td>
<td>Mabley et al. (2003)</td>
<td></td>
</tr>
<tr>
<td>Interleukin-10⁻/⁻</td>
<td>C57BL/6 mice</td>
<td>A3</td>
<td>IB MECA (1 or 3 mg/kg/day b.i.d.)</td>
<td>Reduction of tissue IL-1, IL-6, MIP-1, MIP-2, MPO, and MDA levels</td>
<td>Mabley et al. (2003)</td>
</tr>
</tbody>
</table>

(continued)
maintenance and to sustain normal numbers of naive T cells in the periphery (Cekic et al., 2013). A2A receptors are also important for dampening chondrocyte proinflammatory responses and therefore maintaining a healthy cartilage (Corciulo et al., 2017). A2B KO mice show increased basal cytokines and adhesion molecules even in an unchallenged state (Yang et al., 2006). A2B KO mice develop impaired glucose and lipid metabolism, and their adipose tissue macrophages show decreased alternative activation and increased classical activation with enhanced inflammatory cytokine expression (Csóka et al., 2014).

The duration, magnitude, and composition of the “purinergic halo” surrounding immune cells is tightly calibrated via synthetic and catabolic enzymes, as described above (Antonioli et al., 2012, 2013c; Horenstein et al., 2013) (Table 1). Alterations in the activity of these enzymes can cause immune-mediated disease. CD39 deletion in mice results in impaired glucose tolerance and insulin sensitivity, which is associated with increased systemic levels of proinflammatory cytokines and NF-κB activation in the liver (Enjyoji et al., 2008). These mice also have decreased NKT cell numbers (Beldi et al., 2008). CD73-deficient mice have constitutively increased monocyte adhesion to endothelium in carotid arteries (Koszalka et al., 2004) and increased endothelial cell adhesion factor expression (Zernecke et al., 2006).

The immune system of adenosine deaminase (ADA)-deficient mice is defective both in terms of composition and activity (Whitmore and Gaspar, 2016). These animals have smaller thymi and lymph nodes and fewer cells in lymphoid organs compared with littermate controls (Apasov et al., 2001). They also have severe lymphopenia (affecting T cells, B cells, and NK cells) and impaired cellular and humoral immunity (Whitmore and Gaspar, 2016). Some of these alterations are the result of increased extracellular adenosine accumulation and P1 receptor stimulation, while others are due to intracellular accumulation of deoxyadenosine (Gessi et al., 2007).

CD38 KO mice display a reduced number of peripheral Tregs and invariant NKT cells, due to a NAD⁺-induced cell death process (Chen et al., 2006a,b). In addition, CD38 deficiency in NOD mice accelerates the development of type 1 diabetes (Chen et al., 2006a).

The number and the activity of basophils and mast cells is markedly enhanced in CD203c-deficient mice, making them more susceptible to chronic allergic pathologies (Tsai et al., 2015). In addition, CD203c knockout mice show a reduction of plasmacytoid dendritic cell (DC) numbers in Peyer’s patches in the lamina propria of the small intestine (Furuta et al., 2017).

It is important to stress that with the exception of ADA deficiency, where the immune phenotype of humans is similar to that one observed in mice, the role of purinergic signaling in maintaining immune homeostasis in humans is unknown.

<table>
<thead>
<tr>
<th>Experimental Model</th>
<th>Animal</th>
<th>Molecular Target</th>
<th>Ligand</th>
<th>Pharmacological Effect</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trinitrobenzene sulfonic (TNBS) acid</td>
<td>Sprague-Dawley rats</td>
<td>Adenosine deaminase</td>
<td>IB-MECA (1.5 mg/kg b.i.d.)</td>
<td>Improvement of the clinical and histologic score, and weight gain</td>
<td>Guzman et al. (2006)</td>
</tr>
<tr>
<td>Dinitrobenzene sulfonic (DNBS) acid</td>
<td>Sprague-Dawley rats</td>
<td>Adenosine deaminase</td>
<td>APP, 5, 15, or 45 micromol/kg and EHNA, 10, 30, or 90 micromol/kg</td>
<td>Improvement of the clinical and histologic score, and weight gain</td>
<td>Antonioli et al. (2006a)</td>
</tr>
<tr>
<td>Interleukin-10</td>
<td>C57BL/6 mice</td>
<td>Adenosine deaminase</td>
<td>Pentostatin 0.75 mg/kg</td>
<td>Reduction of free radical production</td>
<td>Brown et al. (2008)</td>
</tr>
</tbody>
</table>
IV. The Concept of Immune-Mediated Inflammatory Diseases

Inflammation is a complex response of the immune system to harmful stimuli affecting the organism, which stimuli include infection, toxic compounds, irradiation, and tissue injury. Inflammation is essential for stemming injurious stimuli and initiating the healing process (Medzhitov, 2008). During the acute phase of inflammation, fluid, inflammatory cells, and proinflammatory mediators accumulate in the extravascular space at the site of injury or invasion. The proinflammatory mediators include interleukins, colony stimulating factors, interferons (IFNs), TNFs, and chemokines, as well as histamine, kinins, coagulation factors, complement factors, nitric oxide, and proinflammatory eicosanoids, such as prostaglandins and leukotrienes (Burnstock and Boeynaems, 2014; Antonioli et al., 2018). In addition to proinflammatory cells and mediators, a wide variety of anti-inflammatory molecular mechanisms and cellular interactions are in place to minimize the extent of tissue injury at the site of the harmful stimulus and surrounding healthy tissue, thus contributing to the eventual restoration of tissue homeostasis (Medzhitov, 2008). The most notable anti-inflammatory mediators are IL-10, TGFs, carbon monoxide, and glucocorticoids. Finally, there are several mechanisms that operate to terminate the inflammatory process and initiate tissue restitution, the mechanisms of which are collectively called inflammatory resolution. Inflammatory resolution is mediated by anti-inflammatory eicosanoids, such as lipoxins, as well as resolvins, protectins, and maresins (Serhan and Levy, 2018).

Deficient regulation of anti-inflammatory processes and resolution of inflammation can lead to overactivation and chronicization of the phlogistic process, which represent a “common soil” of ostensibly unrelated conditions that share common immunologic pathways, collectively named IMIDs (Scrivo et al., 2011). IMID is thus an umbrella term encompassing a set of various diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), uveitis, myasthenia gravis, psoriasis, scleroderma, systemic lupus erythematosus (SLE), glomerulonephritis, chronic obstructive pulmonary disease (COPD), asthma, and inflammatory bowel diseases (IBDs), which are characterized by increased and prolonged inflammation in target organs and frequently by a plethora of systemic effects as well (David et al., 2018).

In addition to the “classical” pro- and anti-inflammatory mediators described above, purines are emerging as powerful extracellular signaling molecules, which orchestrate the onset, magnitude duration, and resolution of the inflammatory response through the activation of purinergic receptors, which are widely expressed on most cell types involved in inflammatory processes (Hasko et al., 1996, 1998, 2000a,b, 2008, 2011; Nemeth et al., 2005, 2006, 2007; Csóka et al., 2008, 2010, 2012, 2015a,b, 2018; Ramanathan et al., 2009; Himer et al., 2010; Hasko and Pacher, 2012; Koscsó et al., 2013; Burnstock and Boeynaems, 2014; Antonioli et al., 2018). Alterations in the purinergic machinery are a common contributor factor to the pathophysiological processes underlying the onset and development of IMIDs.

A. Multiple Sclerosis

MS is a complex, chronic, progressive immune-mediated demyelinating disease causing focal damage to the white matter attacking different regions of the central nervous system. The disease has a relapsing-remitting course and a range of clinical symptoms (e.g., autonomic, visual, motor, and sensory problems), depending on where the demyelination and axonal loss have occurred (Trapp and Nave, 2008). The inflammatory process is characterized by marked infiltration of monocytes, DCs, T and B cells, as well as by activation of resident microglia and macrophages, induction of oxidative stress pathways, and alterations of the blood-brain barrier permeability (Dargahi et al., 2017). Of note, experimental autoimmune encephalomyelitis (EAE) in rodents is the most commonly used model for MS, mimicking several of the key pathophysiological features of the human disease, such as demyelination, axonal loss, inflammation, and gliosis (Constantinescu et al., 2011). Brain sections from MS patients were immunopositive for P2X1, P2X2, P2X3, P2X4, and P2X7 receptors (Amadio et al., 2010). By contrast, the P2X5 receptor was undetectable (Amadio et al., 2010). P2X7 receptor expression is increased on astrocytes in active brain lesions (Narcisse et al., 2005; Amadio et al., 2017) and on microglia of the optic nerve (Matute et al., 2007) of MS patients. P2X7 receptor expression is increased
TABLE 6
Expression of enzyme machinery, nucleoside transporters and purinergic receptors on immune cells and platelets

<table>
<thead>
<tr>
<th>Immune cell types</th>
<th>Platelets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dendritic cells</td>
</tr>
<tr>
<td><strong>P2 Receptors</strong></td>
<td></td>
</tr>
<tr>
<td>P2X1</td>
<td>+</td>
</tr>
<tr>
<td>P2X2</td>
<td></td>
</tr>
<tr>
<td>P2X3</td>
<td>+</td>
</tr>
<tr>
<td>P2X4</td>
<td>+</td>
</tr>
<tr>
<td>P2X5</td>
<td>+</td>
</tr>
<tr>
<td>P2X6</td>
<td>+</td>
</tr>
<tr>
<td>P2X7</td>
<td>+</td>
</tr>
<tr>
<td>P2Y1</td>
<td>+</td>
</tr>
<tr>
<td>P2Y2</td>
<td>+</td>
</tr>
<tr>
<td>P2Y3</td>
<td>+</td>
</tr>
<tr>
<td>P2Y4</td>
<td>+</td>
</tr>
<tr>
<td>P2Y6</td>
<td>+</td>
</tr>
<tr>
<td>P2Y7</td>
<td>+</td>
</tr>
<tr>
<td>P2Y11</td>
<td>+</td>
</tr>
<tr>
<td>P2Y12</td>
<td>+</td>
</tr>
<tr>
<td>P2Y13</td>
<td>+</td>
</tr>
<tr>
<td><strong>Synthetic enzymes</strong></td>
<td></td>
</tr>
<tr>
<td>CD39</td>
<td>+</td>
</tr>
<tr>
<td>CD73</td>
<td>+</td>
</tr>
<tr>
<td>CD39/CD203a</td>
<td>+</td>
</tr>
<tr>
<td><strong>P1 Receptors</strong></td>
<td></td>
</tr>
<tr>
<td>A1</td>
<td>+</td>
</tr>
<tr>
<td>A2A</td>
<td>+</td>
</tr>
<tr>
<td>A2B</td>
<td>+</td>
</tr>
<tr>
<td><strong>Catabolic enzymes and transporters</strong></td>
<td></td>
</tr>
<tr>
<td>Adenosine deaminase</td>
<td>+</td>
</tr>
<tr>
<td>Nucleoside transporters</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CD203a, ectonucleotide pyrophosphatase/phosphodiesterase 3.
on oligodendrocytes also in normal-appearing axon tracts in patients with MS; this may indicate an early role for P2X7 receptors in disease progression (Matute et al., 2007). In addition to the brain, increased P2X7 receptor immunoreactivity was also observed in microglia/macrophages in the spinal cord of MS patients (Yiangou et al., 2006).

The analysis of blood monocytes obtained from MS patients did not reveal any differences in P2X7 receptor expression in comparison with healthy controls (Caragnano et al., 2012). However, a reduction of P2X7 receptor expression was observed in monocytes from patients undergoing treatment with glatiramer acetate (Copolymer 1, Cop-1, or Copaxone), an immunomodulatory drug used to reduce the frequency of relapses in MS (Caragnano et al., 2012).

In the perfused rat optic nerve, oligodendrocytes are vulnerable to sustained activation of P2X7 receptors, and this P2X7 receptor-mediated oligodendrocyte death is associated with microgliosis, demyelination, and axonal damage (Matute et al., 2007). Pharmacological blockade of P2X7 receptors of mice with EAE attenuated tissue damage and neurologic symptoms (Matute et al., 2007). Of interest, the incidence of myelin oligodendrocyte glycoprotein (MOG)-induced EAE in mice deficient in P2X7 receptors was decreased compared with wild-type mice (Sharp et al., 2008). However, once EAE was established in P2X7 receptor-deficient mice, its severity and course were not different from that of wild-type mice. This indicates that P2X7 receptors are necessary for the efficient initiation of EAE, but that EAE can occur, albeit at a decreased level, in the absence of P2X7. In another MOG-induced EAE study, P2X7 receptor-deficient mice developed more severe clinical and pathologic signs of EAE than wild-type mice and antigen-induced proliferation of spleen and lymph node cells from P2X7 receptor-deficient mice was increased compared with cells from wild-type mice (Chen and Brosnan, 2006). Further studies will be necessary to explain the conflicting results between these two studies.

An early study showed that P2X4 receptors were expressed on macrophages infiltrating the brain and spinal cord of rats with EAE (Guo and Schluesener, 2005). P2X4 receptors are also upregulated on microglia during EAE (Vazquez-Villoldo et al., 2014). Both pharmacological blockade and genetic deficiency exacerbated EAE severity, whereas the P2X4 allosteric activator Ivermectin (Stromectol), originally an antiparasitic medication, was beneficial, indicating that P2X4 receptors are protective (Zabala et al., 2018). Mechanistically, P2X4 receptors favored a switch in microglia to an anti-inflammatory phenotype and promoted remyelination.

It is not surprising that of the P2X receptors, the role of P2X7 and P2X4 have been studied in detail, as they are expressed at high levels on immune cells (Suurvali et al., 2017; Csóka et al., 2018). The role of other P2X receptors has not been addressed and should be the subject of future studies.

Histologic analysis revealed an increase in the expression of P2Y11, P2Y12, and P2Y14 receptors in the frontal cortex of MS patients (Amadio et al., 2010). The cellular localization of P2Y12 receptors was studied in detail, and they were found mostly on myelin and interlaminar astrocytes (Amadio et al., 2010). Although the significance of the increase in P2Y11 and P2Y14 receptors is unclear, P2Y12 receptor expression was inversely correlated with myelin lesion formation in patients with MS (Amadio et al., 2010).

In one study, P2Y12 receptor-deficient mice displayed an exacerbated EAE phenotype (Zhang et al., 2017b). In this model, bone marrow-derived DCs from P2Y12 knockout mice undergoing EAE released increased amounts of IL-23, an essential factor for the differentiation of CD4+ T cells toward pathogenetic Th17 cells (Zhang et al., 2017b). In another study, EAE was ameliorated in P2Y12 receptor-deficient mice with decreased brain leukocyte infiltration, less extensive demyelination, and decreased IL-17 expression (Qin et al., 2017). In addition, the anticoagulant drugs clopidogrel (P2Y12 inverse agonist, Plavix) and ticagrelor (P2Y12 neutral antagonist, Brilinta) alleviated the severity of EAE and inhibited Th17 differentiation (Qin et al., 2017). It is unclear why the two studies had opposing results, as they appeared to use the same mice and model. Therefore, this discrepancy as well as the role of other P2Y receptors awaits further clarification.

Early studies reported that A1 receptor mRNA and protein levels were reduced in blood and brain monocytes, macrophages, and microglia from patients with MS (Johnston et al., 2001) and microglia in mice during EAE (Tsutsui et al., 2004). This deficit in A1 receptors appears to contribute to the course of EAE, as A1 receptor-deficient mice showed exacerbated disease and had increased myelin and axonal loss (Tsutsui et al., 2004). Macrophages from A1 receptor-deficient mice had increased expression of proinflammatory cytokines and metalloproteinase-12.

Vincenzi et al. (2013) demonstrated increased expression A2A receptors on lymphocytes from MS patients compared with healthy individuals (Vincenzi et al., 2013). The authors speculated that this A2A receptor overexpression is a compensatory mechanism aimed at curbing the inflammatory process, as in vitro stimulation of A2A receptors of lymphocytes from multiple sclerosis patients suppressed the release of proinflammatory cytokines (TNF, IL-1β, IL-6, IL-17, and IFN-γ) and decreased cell proliferation, NF-κB activation, and the expression of the adhesion molecule VLA-4 (Vincenzi et al., 2013). Positron emission tomography demonstrated increased A2A receptor expression in the brains of MS patients (Rissanen et al., 2013). At this point it is unclear which cell types were responsible for this increase.
Increased A2A receptor expression was also observed on lymphocytes from EAE mice. Pharmacological stimulation of A2A receptors with the selective agonist CGS21680 starting at the time of immunization with myelin oligodendrocyte glycoprotein (MOG) caused a significant amelioration of EAE clinical severity (Liu et al., 2016). In vitro cultured lymphocytes from immunized mice, CGS21680 caused a marked decrease in lymphocyte proliferation and Th1, Th2, and Th17 lymphocyte count and an increase in Treg numbers (Liu et al., 2016). Using both pharmacological and genetic manipulation of A2A receptors in mice with EAE, Ingwersen at al. (2016) demonstrated that while early activation of A2A receptors ameliorated the course of EAE, A2A receptor activation after disease onset aggravated the disease process (Ingwersen et al., 2016). In addition, bone marrow transfer studies demonstrated that A2A receptor expression on nonimmune cells such as neurons in the brain, choroid plexus, meninges, hippocampus, and cerebellum contributed to EAE development, while A2A receptor expression on immune cells (most likely lymphocytes) was essential for limiting the severity of the inflammatory response and disease progression (Mills et al., 2012b). A further complicating factor is that A2A receptors appear to be important for the maintenance of the integrity of blood-brain barrier, and thereby modulating immune cell influx into the brain (Carman et al., 2011; Kim and Bynoe, 2015; Liu et al., 2018). Thus, the picture is complex and further studies will be required to unravel the precise role of A2A receptors in EAE.

Similar to A2A receptors, A2B receptors are upregulated on peripheral blood leukocytes of MS patients (Wei et al., 2013). A2B receptor-deficient mice or mice treated with the selective A2B receptor neutral antagonist CVT-6883 (3-ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione; developed less severe EAE compared with wild-type or vehicle-treated mice, respectively (Wei et al., 2013). This decrease in EAE severity was associated with decreased Th17 and Th1 cell responses in vivo.

Given the central role of CD39 in switching from ATP-mediated proinflammatory responses to the overall anti-inflammatory nature of adenosine-mediated responses (Antonioli et al., 2013c), the role of CD39 in regulating MS is an important question. In an early study, Borsellino et al. (2007) found a strikingly reduced number of CD39+ Tregs in the blood. Fletcher et al. (2009) confirmed this finding, as they observed a deficit in the relative frequency and the suppressive function of CD4+CD25+FoxP3+CD39+ Treg cells in multiple sclerosis patients. Despite these findings, the role of CD39 in modulating the development and course of MS is still elusive. CD39 on DCs was found to be important for limiting the onset and severity of EAE (Mascalfroni et al., 2013) and CD39-deficient CD4 T cells showed an enhanced capability to drive EAE progression (Wang et al., 2014b). Nucleoside, triphosphate diphosphohydrolase-2, which can also degrade ATP, was found to be down-regulated in EAE, and this decrease was associated with the severity of disease symptoms (Jakovljevic et al., 2017).

CD73-deficient mice were resistant to EAE, as the entry of lymphocytes into the central nervous system was inhibited in the absence of CD73 (Mills et al., 2008, 2012a). This may be because adenosine generated by CD73 is a key factor for opening the blood-brain barrier and therefore allowing lymphocyte influx (Bynoe et al., 2015).

Despite the observation that CD38 is highly expressed in brain and lymphocytes obtained from MS patients (Penberthy and Tsunoda, 2009), the role of CD38 and the CD38-CD203 axis, is still completely unexplored. Thus, more research is needed to better appreciate the potential relevance of the CD38-CD203 axis in MS pathogenesis and progression.

An increase in adenosine deaminase (ADA) activity was observed in the serum (Polachini et al., 2014) and cerebrospinal fluid (Samuraki et al., 2017) of MS patients. By contrast, ADA enzymatic activity in lymphocytes and platelets was reduced (Vivekanandhan et al., 2005; Spanevello et al., 2010a,b). As no preclinical studies have been performed to study the role of ADA in regulating MS, the role of these changes in ADA expression and activity is unclear.

Animal models of MS as well as studies performed on samples obtained from MS patients highlighted a key role of purinergic receptors, such as P2X7, P2Y12, or A2A and A2B in the onset and progression of this disorder. Indeed, both in vitro and in vivo experiments showed that the pharmacological or genetic manipulation of these receptor subtypes altered disease features, indicating their putative relevance as molecular targets for the development of novel pharmacological entities useful to counteract MS.

B. Uveitis

Uveitis is an inflammatory condition directed against the uvea, the vascular, pigmented middle coat of the eye wall, composed of the iris anteriorly, the ciliary body indirectly, and the choroid posteriorly (Read, 2006). Uveitis, especially if untreated, can lead to significant visual deficit and blindness (Caspi, 2010). Based on the etiology, uveitis can be distinguished as 1) infectious uveitis caused by an innate inflammatory reaction triggered by environmental “danger” signals (microbial) and 2) noninfectious uveitis, which is believed to be autoimmune or immune mediated (Caspi, 2010; Chen and Sheu, 2017).

The role of P2 receptors in regulating uveitis is not well understood. Zhao et al. (2016) demonstrated that oxidized ATP (oxATP) almost completely abolished the onset of experimental autoimmune uveitis (EAU)
elicited by immunization of mice with the human interphotoreceptor retinoid-binding protein peptide IRBP1–20 (Zhao et al., 2016). OxyATP-treated mice displayed fewer autoreactive T cells, especially Th17 autoreactive T cells, indicating that P2X7 receptors promote disease through inducing Th17 cell expansion (Zhao et al., 2016).

The CD25+CD11c+ DC subset has a critical role in eliciting the Th17 autoreactive T cell response in IRBP1–20–elicited EAU, and activated γδ T cells promote Th17 cell development (Liang et al., 2012, 2015). Adenosine receptor stimulation differentially affects the immune response depending on the disease stage (Liang et al., 2014). Treating mice with the nonselective adenosine receptor agonist NECA during the induction phase (0 days postimmunization) had a suppressive effect on disease development and Th17 responses (Liang et al., 2014), whereas when administered once the autoimmune response had already been initiated (7 days postimmunization), NECA enhanced disease activity and Th17 responses (Liang et al., 2014). The selective A2A agonist CGS21680 recapitulated the biphasic effect of NECA, whereas BAY 60-6538 (2-[(3,4-dimethoxyphenyl)methyl]-7-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1H)-one), an A2B agonist, moderately augmented disease activity irrespective of the timing of the treatment (Liang et al., 2014). The stimulatory effect of BAY 60-6538 was confirmed in another study where four injections of this drug between days 0 and 10 postimmunization enhanced EAU development and Th17 cell numbers and IL-17 production (Chen et al., 2015). The enhancing effect of BAY 60-6538 on the Th17 response was markedly reduced in mice lacking γδ T cells, suggesting that the proinflammatory effect of BAY 60-6538 required γδ T cells (Chen et al., 2015)). Since BAY 60-6538 was unable to directly stimulate γδ T cells but augmented the ability of DCs to activate γδ T cells, the authors suggested that the proinflammatory effects of BAY 60-6538 were primarily mediated by A2B receptors on DCs (Chen et al., 2015). In another EAU model, CGS21680 administered at the peak of EAU accelerated the resolution of disease (Lee et al., 2016). Taken together, exogenous A2A receptor stimulation can both increase and decrease disease activity in EAU depending on the timing of stimulation and the model used, whereas exogenous A2B receptor stimulation is proinflammatory across time points and models. In contrast, A2A receptor KO and wild-type mice had a comparable course of EAU, indicating that endogenous adenosine stimulating A2A receptors has no effect on the disease (Lee and Taylor, 2013).

A study performed by Bar-Yehuda et al. (2011) demonstrated that the selective A3 receptor agonist CF101 was protective in an experimental animal model of uveitis. CF101 orally administered improved uveitis clinical scores and ameliorated the pathologic manifestations of the disease (Bar-Yehuda et al., 2011). In addition, CF101 acted as an immunomodulatory agent and suppressed antigen-specific proliferation and cytokine production of autoreactive T cells (Bar-Yehuda et al., 2011).

The role of purine metabolic enzymes in regulating uveitis is incompletely defined. CD73 expression was downregulated on γδ T cells during the preclinical or immunization phase (before day 7) of uveitis, whereas it was restored later during the clinical phase (Liang et al., 2016a). CD73 on αβ T cells remained unchanged throughout the course of EAU. As mice lacking γδ T cells adoptively transferred with CD73 KO cells had increased clinical score of EAU compared with mice transferred with CD73 sufficient γδ T cells, it was concluded that CD73 on γδ T cells protect against EAU (Liang et al., 2016a).

In a study aimed at evaluating the role of ADA in EAU, it was observed that ADA suppressed the course of EAU when given 8–14 days postimmunization and increased it when given either before or after this period (Liang et al., 2016b). Mice that received ADA at 8–14 days postimmunization had milder disease and recovered earlier than the untreated animals. In addition, ADA treatment at this time decreased serum IL-6 and IL-17 levels but induced a slight increase in serum IFN-γ and IL-10 concentrations (Liang et al., 2016b). The protective role of increased ADA activity at day 8 was confirmed by treating mice with the ADA inhibitor EHNA, which augmented both the course of EAU and IL-17 plasma levels (Liang et al., 2016b). The differential effect of ADA at different time point may reflect the differential role of adenosine receptors described above.

At present, the evidence about the role of the purinergic system in the pathophysiology of uveitis is few and fragmentary and further investigations are needed. In particular, there is a significant knowledge gap of the role of purinergic enzyme machinery in regulating the onset and development of uveitis. Nowadays, the available data indicate encouraging anti-inflammatory effects of adenosine and their agonists CGS21680 and CF101, acting via A2A and A3 adenosine receptors, respectively, thus prompting their use for the treatment inflammatory ophthalmic conditions. However, future studies are needed to evaluate better the relative contribution of adenosine receptors in shaping the activity of specific immune cells during uveitis.

C. Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune disease caused by antibody-mediated blockade of neuromuscular transmission that results in muscle weakness and fatigue (Conti-Fine et al., 2006). The autoantibodies are generated by B cells in a T cell-dependent fashion and are reactive against nicotinic acetylcholine receptors (Vrolix et al., 2010; Meriggioli and Sanders, 2012).

Li et al. (2012) observed decreased A2A receptor expression on both CD4+ T cells and B cells residing in spleen and lymph nodes of animals subjected to experimental
autoimmune myasthenia gravis (EAMG) (Li et al., 2012). The administration of CGS21680 29 days post EAMG induction (therapeutic treatment) ameliorated disease severity and decreased the number of Th1 and Th2 cells while increasing the number of T<sub>reg</sub> cells, thus indicating that targeting A<sub>2A</sub> receptors may represent putative therapeutic applications for MG (Li et al., 2012).

A recent paper by Oliveira et al. (2015) proposed that insufficient adenosine levels may contribute to deregulated immune cell function and neuromuscular transmission in myasthenic animals (Fig. 2). In EAMG animals, the expression of CD73 on T<sub>reg</sub> cells was found to be decreased (Oliveira et al., 2015), which may result in impaired suppression of effector T cells contributing to the disease process (Li et al., 2012). In addition, the increased ADA activity observed in EAMG rats may also potentially aggravate adenosine deficiency and therefore autoimmunity (Oliveira et al., 2015).

In line with what was observed in this EAMG rat model (Oliveira et al., 2015), myasthenic patients showed an increase of total ADA activity (Chiba et al., 1990, 1995). Of note, the level of ADA2 was positively correlated with clinical MG grade (Chiba et al., 1995). Clearly, further studies aimed at unraveling the role of purinergic signaling in MG are needed.

D. Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a common autoimmune disease, which causes both joint inflammation and systemic complications, progressive disability, early death, and high socioeconomic costs (McInnes and Schett, 2011). Macrophages, DCs, T cells, and B cells accumulate in the joints, where they produce autoantibodies, proinflammatory cytokines, and bone destructive mediators (Weyand et al., 2009). Interactions between chronically stimulated immune cells and stromal cells, such as endothelial cells, vascular smooth muscle cells, and synovial fibroblasts are also critical to the onset and progression of this disorder (Weyand et al., 2009).

Extracellular ATP levels are increased in the synovial fluid of RA patients (Dowd et al., 1998). Human synoviocytes were shown to express P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>7</sub>.

![Fig. 2. Schematic representation depicting the role of the purinergic system in neuroimmunological alterations in an experimental model of experimental autoimmune myasthenia gravis. In healthy conditions, endogenous adenosine generated from the activity of CD73 counteracts the proinflammatory activity of T<sub>eff</sub> cells, by acting on A<sub>2A</sub> receptor expressed on them and by increasing the activity of T<sub>reg</sub> cells. In addition, in the motor endplate, adenosine, arising from ATP degradation, facilitates acetylcholine release via the stimulation of A<sub>2A</sub> receptors expressed at the presynaptic level. In myasthenic animals, there is reduced production of endogenous adenosine. In addition, adenosine degradation is increased, which is related with an increase in plasma adenosine deaminase activity. This results in increased production of autoAbs against nAChR and thus a loss of peripheral tolerance to nAChR. ACh, acetylcholine; ADA, adenosine deaminase; nAChR, nicotinic receptor.](image-url)
to be investigated. P2X4 receptors were recently shown to (Varani et al., 2011; Ravani et al., 2017). A3 receptors IL-6 and matrix metalloproteinases MMP-1 and MMP-3 of the pro-inflammatory cytokines TNF- nuclear factor- methyluronamide (Cl-IB-MECA) respectively, reduced P2X6, and P2X7 but not P2X3 receptors at the messenger RNA level (Caporali et al., 2008). Pharmacological studies have shown that P2X7 stimulation on these cells increases the production of IL-6 (Caporali et al., 2008), a major driver of the pathophysiology of RA. In a rat streptococcal cell wall arthritis model, P2X7 receptor expression was detected in inflamed synovial tissue after the onset of disease, and P2X7 receptor blockade with the selective antagonist AZD9056 suppressed articular inflammation and erosive progression (McInnes et al., 2014). Blockade of P2X7 receptors also ameliorated pathologic changes in a collagen-induced arthritis model in mice, which was associated with decreased differentiation of pathogenic Th17 cells (Fan et al., 2016). Unfortunately, AZD9056 failed to improve clinical outcomes in a phase 2 clinical trial in RA (Keystone et al., 2012). Similarly, CE-224,535 (2-chloro-N-[(1-hydroxycycloheptyl) methyl]-5-[4-[2(R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide), another P2X7 receptor antagonist was also not efficacious, compared with placebo, for the treatment of RA in patients with an inadequate response to methotrexate (an allosteric inhibitor of dihydrofolate reductase), a commonly used disease modifying immunosuppressive drug (Stock et al., 2012).

Klein et al. (2012) reported that P2X4 receptor stimulation increased the release of brain-derived neurotrophic factor, a neuromodulator involved in nociceptive hypersensitivity in the central nervous system, by synoviocytes from RA patients (Klein et al., 2012). The question of whether P2X4 receptors contribute to pain in RA remains to be investigated. P2X4 receptors were recently shown to promote joint inflammation and destruction in collagen-induced arthritis in mice (Li et al., 2014). Mechanistic studies showed that in both synovial cells obtained from human patients with RA and arthritic mice, targeting P2X4 by antisense RNA suppressed the production of the pro-inflammatory cytokines IL-1β, TNF, and IL-6 (Li et al., 2014). In addition, P2X4 receptor silencing suppressed NLRP1 inflammasome activation (Li et al., 2014).

mRNA for all four adenosine receptors was detected on human synoviocytes (Boyle et al., 1996; Hasko et al., 2008, 2018). Varani et al. (2009) demonstrated increased expression of A2A and A3 receptors on lymphocytes and neutrophils isolated from RA patients in comparison with healthy subjects. No changes in A1 or A2B receptors were observed (Varani et al., 2009, 2011; Ravani et al., 2017). The incubation of lymphocytes from RA patients with the selective A2A and A3 receptor agonists CGS 21860 and 2-chloro-N6-(3-iodobenzyl)-adenosine-5’-N-methyluronamide (Cl-IB-MECA) respectively, reduced nuclear factor-κB activation and diminished the release of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 and matrix metalloproteinases MMP-1 and MMP-3 (Varani et al., 2011; Ravani et al., 2017). A3 receptors were found to be highly expressed in inflammatory tissues isolated from rats with adjuvant-induced arthritis, especially synovia, peripheral blood mononuclear cells and draining lymph nodes (Fishman et al., 2006; Rath-Wolfson et al., 2006). A3 receptors were also over-expressed in peripheral blood mononuclear cells of RA patients compared with healthy subjects (Madi et al., 2007).

2-(Cyclohexylethythithio) adenosine 5’-monophosphate, a prodrug that is degraded to a selective A2A receptor agonist by CD73, suppressed joint inflammation in mice with collagen-induced arthritis. The cellular targets of the drug appeared to be monocytes and neutrophils. Interestingly, synovial cytokines were not affected (Flogel et al., 2012).

An early study showed that A3 receptor stimulation with N6-(3-iodobenzyl)-adenosine-5’-N-methyluronamide (IB-MECA also called CF101) reduced the severity of joint inflammation and inhibited the production of MIP-1α, IL-12, and reactive nitrogen species in the paws and suppressed neutrophil infiltration (Szabo et al., 1998). Subsequent studies confirmed the salutary effects of IB-MECA in a rat RA model as well (Bar-Yehuda et al., 2009). Mechanistic studies demonstrated that the anti-inflammatory effects of IB-MECA were associated with reduced expression and activation of phosphoinositide 3-kinase, protein kinase B/Akt, and NF-κB (Fishman et al., 2006; Ochaion et al., 2008). Despite the promising results with IB-MECA in animal models, it failed to improve the course of RA in human patients (Silverman et al., 2008).

Several studies reported increased CD39 expression on CD4+ T cells of RA patients (Potocnik et al., 1990; Berner et al., 2000; Dos Santos Jaques et al., 2013). FOXP3+ CD39+ Treg cells are enriched in the joints of patients suffering from RA, and these cells are potent suppressors of many effector T-cell functions, including production of IFN-γ, TNF-α, and IL-17F (Herrath et al., 2014). Although no studies have directly tested the role of CD39 in regulating the course of RA, there is evidence that CD39 mediates the anti-arthritic effects of various treatment modalities. For example, in a murine model of arthritis, CD39 blockade reversed the anti-arthritic effects of methotrexate, a mainstay of RA therapy (Peres et al., 2015). Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, also attenuates experimental murine arthritis through CD39 (Veras et al., 2015). Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorated murine collagen-induced arthritis in a CD39-dependent manner (Chen et al., 2013).

In contrast to CD39, CD73 was downregulated on CD4+ cells and Foxp3+ Treg at the site of inflammation in patients with RA (Herrath et al., 2014). On the other hand, CD73 was increased on neutrophils and monocytes recovered from the synovial fluid of arthritic mice (Flogel et al., 2012). CD73-deficient mice were found to be more susceptible to collagen-induced arthritis compared with wild-type mice (Chrobak et al., 2015). They had increased
production of proinflammatory cytokines in their joints and increased Th1 responses. Studies using bone marrow chimeric mice demonstrated that CD73 on non-hematopoietic cells was responsible for the CD73 protection against arthritis (Chrobak et al., 2015).

ADA levels are increased in plasma of patients with RA (Vinapamula et al., 2015; Valadbeigi et al., 2019 and reviewed in Antonioli et al., 2012). Synoviocytes obtained from RA patients had increased ADA mRNA expression (Nakamachi et al., 2003). It is conceivable that increased ADA is a pathogenic factor, as increased deamination of adenosine will result in its lowered bioavailability and decreased adenosine receptor-mediated suppression of inflammation.

Methotrexate has been in use for the treatment of RA since the 1980s, and it is still often the first line medication for RA patients (Friedman and Cronstein, 2018). There is a large body of evidence that methotrexate mediates its anti-inflammatory effect through increasing ATP release (Morabito et al., 1998; Montesinos et al., 2007), which is subsequently degraded to adenosine through ectonucleotidases (Montesinos et al., 2007), which in turn suppresses inflammation (Montesinos et al., 2000). Recently, it was observed that methotrexate nonresponsiveness in RA patients was associated with low expression of CD39 on Treggs (Peres et al., 2015; Gupta et al., 2018). This suggests that CD39 expression on Treggs could be a noninvasive biomarker for the early identification of patients who are unlikely to respond to methotrexate therapy.

Based on the above mentioned evidence a promising novel therapeutic approach for the treatment of RA may involve targeting adenosine receptors (mainly the A2a and A2b receptor subtypes). Alternatively, indirect targeting of adenosine receptors by enhancing endogenous adenosine concentration at inflamed sites by the pharmacological blockade of ADA or nucleoside transporters, may represent a novel therapeutic approach.

**E. Scleroderma**

Scleroderma, which is also called systemic sclerosis, is an autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs as well as by vasculopathy (Denton and Khanna, 2017). Salient features of the tissue lesions in scleroderma are early microvascular damage, mononuclear-cell infiltrates, and slowly developing fibrosis (Gabrielli et al., 2009). In later stages of scleroderma, the main findings are very densely packed collagen in the dermis and other organs, loss of cells, and atrophy (Gabrielli et al., 2009; Denton and Khanna, 2017).

There is a growing body of evidence indicating that adenosine has an important role in tissue remodeling and dermal fibrosis (Chan et al., 2013; Hu et al., 2013; Perez-Asó et al., 2014; Zhang et al., 2017a; Karmouty-Quintana et al., 2018). A2A receptor activation causes dermal wound closure and increased dermal matrix deposition in vitro (Montesinos et al., 2004; Cronstein, 2006a; Scheibner et al., 2009). In agreement with these in vitro profibrotic effects of A2A receptor activation, both genetic deletion and pharmacological inhibition of A2A receptors with ZM241385 (4-[2-(7-amino-2-(2-furyl)-1,2,4-triazolo[2,3-a][1,3,5]triazin-5-yl-amino)ethyl phenol), a neutral antagonist, prevented dermal fibrosis in mice challenged with subcutaneous bleomycin, a model of human scleroderma (Chan et al., 2006). Another study utilizing a structurally different A2A antagonist, KW6002 ((E)-8-(3,4-dimethoxy styryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione), also confirmed reduced severity of bleomycin-induced dermal fibrosis (Zhang et al., 2017a).

Subcutaneous treatment of mice with bleomycin upregulates A2B receptor transcript levels in the skin (Karmouty-Quintana et al., 2018). Pharmacological blockade of A2B receptors by GS-6201 reduced the production of profibrotic mediators (fibronectin, MCP1, IL-6, and α-SMA) in the skin and attenuated dermal fibrosis of mice in bleomycin-induced as well as genetic [mutant tight-skin (TSK1/+ mice) models of human scleroderma (Karmouty-Quintana et al., 2018). While no differences in A2B receptor expression were found between healthy and sclerotic human skin (Karmouty-Quintana et al., 2018), a reduction in density and function of A2B receptors was noted in neutrophils of patients affected by scleroderma compared with healthy patients (Bazzichi et al., 2005). The significance of this decrease of A2B receptor expression and function in scleroderma patients is unclear.

Consistent with the generally profibrotic effects of adenosine, CD39 knockout (KO) animals as well as CD39/CD73 KO exhibited reduced skin fibrosis upon bleomycin challenge (Fernandez et al., 2013).

Genetic deletion of ADA leads to elevated adenosine levels and spontaneous dermal fibrosis in mice (Fernandez et al., 2008). Although increased ADA activity has been reported in plasma of scleroderma patients (Sasaki and Nakajima, 1992; Meunier et al., 1995), it is unclear whether the increased ADA is a causative factor in scleroderma.

In summary, increased adenosine and A2A and A2B receptors contribute to scleroderma development in mice. The role of P2 receptors is unknown and will need to be defined in the future.

**F. Psoriasis**

Psoriasis vulgaris, commonly known as plaque psoriasis, is a chronic inflammatory skin disease characterized by skin plaques and systemic symptoms. The immunopathogenesis of psoriasis involves both the innate and adaptive immune systems (Lowes et al., 2014). The immune circuits that normally participate in the regulation of skin homeostasis, become abnormally activated and amplified in psoriatic patients, leading to an excessive and rapid growth of the epidermal layer of the skin.
Activated myeloid DCs release IL-23 and IL-12, which stimulate Th17, Th22, and Th1 cells to release copious amounts of psoriatic cytokines such as IL-17, IL-22, TNF, and IFN-γ, which promote keratinocyte hyperproliferation (Lowes et al., 2014).

Keratinocytes express all P2X and P2Y receptor subtypes so far cloned, except for P2Y14 (Dixon et al., 1999; Burrell et al., 2003; Inoue et al., 2005; Pastore et al., 2007; Ishimaru et al., 2013). IFN-γ upregulated the expression of P2X7 and P2Y1 receptors on human keratinocytes, suggesting a possible involvement of these receptor subtypes in the pathophysiology of psoriasis (Pastore et al., 2007). An increase in P2X7 receptor expression was also reported in nonlesional skin of psoriatic patients in comparison with healthy skin tissue, leading the authors to hypothesize that P2X7 receptor dysregulation in psoriasis precedes the onset of inflammatory lesions (Killeen et al., 2013). In healthy skin explants, the pharmacological stimulation of P2X7 with BzATP induced a significant increase in vascular endothelial growth factor, IL-23, and IL-6 expression, indicating that P2X7 receptor activation may be an initiating factor in psoriasis development (Killeen et al., 2013).

Although both P2Y6 (Uratsuji et al., 2012) and P2Y11 receptors (Ishimaru et al., 2013) can contribute to proinflammatory responses of keratinocytes in vitro, the relevance of these findings for psoriasis is still incompletely understood.

Normal human keratinocytes and normal human skin express mainly A2B receptors and detectable levels of A2A receptors, whereas the levels of A1 and A3 receptor mRNA are negligible (Andres et al., 2017). Psoriasis is associated with an upregulation of A2A and downregulation of A2B receptors in the psoriatic skin (Andres et al., 2017). Since A2A receptors augment keratinocyte proliferation and A2B receptors arrest it (Fig. 3) (Andres et al., 2017), it is conceivable that the increase in A2A and decrease in A2B receptor expression observed in psoriatic patients contribute the hyperkeratosis process (Fig. 3) (Lowes et al., 2014). In contrast to keratinocytes, A2A receptors are downregulated on effector CD4+ T cells from patients with psoriasis compared with healthy subjects (Han et al., 2018), while A3 receptors are overexpressed in peripheral blood mononuclear cells of psoriatic patients (Ochaion et al., 2009). A randomized, double-blind, placebo-controlled trial demonstrated that IB-MECA improved the clinical symptoms of psoriasis (David et al., 2016). Although this study did not investigate the mechanisms underlying the beneficial effects of IB-MECA, a subsequent study found that A3 receptor activation suppressed keratinocyte proliferation and IL-17 and IL-23 production by keratinocytes (Cohen et al., 2018).

In conclusion, novel therapies could be derived for hyperproliferative skin diseases, such as psoriasis, based on the intriguing dual roles played by A2A and A2B adenosine receptors in modulating keratinocyte proliferation. Future studies should inform us on whether A2A agonists could be used to reduce inflammation. In addition, it should be of interest to evaluate the influence of existing therapeutic approaches for psoriasis in regulating adenosine receptor expression to determine whether adenosine receptor expression may serve as a biomarker in the trajectory of psoriatic pathology.

G. Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, relapsing/remitting, and multisystemic autoimmune disease with heterogeneous clinical manifestations. The disease can have dermatological, musculoskeletal, renal, respiratory, cardiovascular, hematologic, and neurologic consequences (Moulton et al., 2017). Major pathogenetic factors of SLE comprise immune responses against endogenous nuclear antigens, increased autoantibody production, increased apoptosis, and deficient clearance of apoptotic cells (Moulton et al., 2017). As a result of these processes, immune cells secrete aberrant amounts of cytokines and other soluble proinflammatory mediators, which cause inflammation and the destruction of end-organs (Moulton et al., 2017). The majority of SLE patients display elevated production...
of type I interferons and increased expression of type I IFN-regulated genes (Ronnblom and Pascual, 2008).

There is an increasing appreciation of the notion that alterations of the purinergic machinery can contribute to the pathogenesis of SLE (Forchap et al., 2008; Portales-Cervantes et al., 2010; Loza et al., 2011; Sipka, 2011; Saghiri et al., 2012; Bortoluzzi et al., 2016). Portales-Cervantes et al. (2010) and Forchap et al. (2008) both studied the role of the most frequent, loss-of-function 1513 A→C single nucleotide polymorphism of P2X7 receptors in human SLE. Both studies failed to find differences in allele frequencies of this polymorphism when comparing sporadic cases of SLE and healthy controls. Although ATP-induced IL-1β release was significantly decreased in SLE patients with the 1513 A→C genotype (Portales-Cervantes et al., 2010), the significance of this finding is unclear. In murine studies, pharmacological P2X7 receptor blockade attenuated the pathology of lupus nephritis, the mechanism of which appeared to be a compensatory mechanism to counteract the proinflammatory milieu of SLE (Bortoluzzi et al., 2016). Turner et al. (2007) reported that P2X7 receptors were upregulated in the kidney (Arulkumaran et al., 2013). Turner et al. (2007) observed that B220+ CD4+CD8−CD45RO+CD69+ macrophages and mesangial cell activation (Scindia et al., 2010; Scindia et al., 2011) included glomerular infiltration of macrophages and neutrophils, and renal injury (Zhang et al., 2011). The role of P2X7 receptors in SLE, as CGS21680 treatment of MRL/lpr mice suppressed T cell activation, autoantibody production, and renal injury (Zhang et al., 2011). The role of A1, A2B, and A3 receptors in SLE is unknown.

CD39 expression was found to be defective on freshly isolated Treg cells of lupus subjects with minimally active disease compared with patients with active disease or healthy controls (Loza et al., 2011). In addition, nonregulatory T cells were deficient in their capacity to upregulate expression of CD39 upon CD3 stimulation specifically in patients with minimally active disease. Although the reason why patients with minimally active disease had defective CD39 remained unclear, the authors proposed that defective CD39 expression might be a useful biomarker for early detection of the disease, prior to the onset of symptoms (Loza et al., 2011). A recent study employing CD39-deficient mice undergoing pristane-induced lupus demonstrated that CD39 controlled autoimmunity and disease symptoms, shedding some light on the role of CD39 in lupus (Knight et al., 2018).

A defective activity was reported also for 5′-nucleotidase in lymphocytes isolated from lupus patients (Stolk et al., 1999). Although this study did not provide more specific evidence, it is likely that the 5′-nucleotidase activity was due to CD73, as this enzyme is the major cell-associated 5′-nucleotidase (Yegutkin, 2008). Similar to CD39, CD73 protected against pristane-induced lupus (Knight et al., 2018), suggesting that the CD39-CD73-adenosine axis may be important for curbing inflammation in SLE.

### H. Glomerulonephritis

Glomerulonephritis is a condition of glomerular inflammation, which manifests as hematuria and proteinuria (Anders, 2013; Liu and Chun, 2018). It encompasses a spectrum of kidney diseases that collectively are the third leading cause of end-stage renal disease. The incidence of primary glomerulonephritis varies between 0.2 and 2.5 per 100,000 per year (Liu and Chun, 2018). The pathogenesis of glomerulonephritis is complex. Several factors can trigger and contribute to the progression of glomerular injury. These include, but are not limited to, genetic predisposition, autoimmunity, malignancy, infections, diabetes, hypertension, and exposure to drugs (Liu and Chun, 2018). Major pathophysiological factors include glomerular infiltration of macrophages and neutrophils and mesangial cell activation (Scindia et al., 2010; Kitching and Hutton, 2016).

Several P2 receptors are expressed in the healthy kidney (Arulkumaran et al., 2013). Turner et al. (2007) reported that P2X7 receptors were upregulated in the kidney of both patients and mice with glomerulonephritis (Turner et al., 2007). In animal models of antibody-mediated glomerulonephritis, P2X7 receptor deficiency or pharmacological antagonism prevented macrophage infiltration and protected against kidney
injury (Taylor et al., 2009). Pharmacological blockade or siRNA-mediated silencing also prevented kidney injury in MRL/lpr mice, a model of lupus-induced glomerulonephritis (Zhao et al., 2013). The protective effect of P2X7 blockade was associated with decreased NLRP3 inflammasome activation and IL-1β release (Zhao et al., 2013). In a recent murine study, systemic injection of a nanobody against the P2X7 receptors blocked the receptor on T cells and macrophages and ameliorated antibody-induced glomerulonephritis (Danquah et al., 2016). Other than the P2X7 receptor, the only other receptor whose role has been tested in glomerulonephritis is the P2Y1 receptor, the deficiency of which was protective in mice with antibody-mediated glomerulonephritis (Hohenstein et al., 2007).

Of all the adenosine receptors, the A2A receptor is the only one whose role has been investigated in regulating glomerulonephritis. In the first study on this topic, increased expression of A2A receptors on macrophages was found in the glomeruli of rats with antibody injection-induced glomerulonephritis (Garcia et al., 2008). Pharmacological activation of A2A receptors with CGS21680 prevented the infiltration of leukocytes into the kidney, counteracted glomerular inflammation, and protected the kidney from inflammatory injury in this model (Garcia et al., 2008). The protective effect of A2A receptor stimulation was subsequently confirmed in MRL/lpr mice, as CGS-21680 treatment caused reduced proteinuria, and blood urea and creatinine levels, as well as an improvement in renal histology (Zhang et al., 2011). Renal tissue had reduced macrophage and T-cell infiltration, as well as attenuated MCP-1, IFN-γ, and MHC-II expression (Zhang et al., 2011). CGS21680 treatment also reduced serum anti-dsDNA levels and renal immune complex deposition (Zhang et al., 2011). A recent study using A2A receptor KO mice showed that endogenous adenosine protected mice from glomerulonephritis through A2A receptors, as the deficient mice were more prone to kidney injury and had increased renal inflammatory cytokines and glomerular hyalinosis compared with wild-type animals (Truong et al., 2016). Using macrophage depletion and reconstitution with wild-type or A2A receptor-deficient macrophages during the established phase of glomerulonephritis, the authors demonstrated that macrophage A2A receptors were central to the A2A receptor-mediated protection against glomerulonephritis (Truong et al., 2016).

I. Chronic Obstructive Pulmonary Disease

COPD is a progressive inflammatory condition characterized by a progressive and irreversible deterioration of lung function due to airflow obstruction, destruction of parenchyma, and emphysema (MacNee and Tudor, 2009; Rovina et al., 2013). Tobacco smoking is the most common cause of COPD in the developed world, whereas indoor air pollution due to poorly ventilated cooking fires is a major cause in developing countries (Rovina et al., 2013). The major pathophysiological factor leading to COPD is airway inflammation caused by the inhaled irritants. The primary target cells of the irritants are epithelial cells and resident (alveolar) macrophages, which become activated and release chemotactic mediators leading to the recruitment of further inflammatory cells (CD8+ T cells, neutrophils, monocytes, and lymphocytes) into the lung. The resulting multicellular infiltrate is central to the maintenance of the chronic inflammatory process, which persists even after the exposure to irritants ceases (Rovina et al., 2013).

There has been a steadily increasing interest in the involvement of purinergic signaling in the pathophysiology of COPD (Polosa and Blackburn, 2009; Mortaz et al., 2010; Pelleg et al., 2016). Lommatzsch et al. (2010) measured ATP concentrations in alveolar bronchoalveolar lavage (BAL) fluid and found that COPD patients had elevated ATP levels compared with controls (Lommatzsch et al., 2010). In patients with COPD, BAL fluid ATP concentrations correlated inversely with lung function and positively with BAL fluid neutrophil counts. BAL fluid macrophages isolated from patients with COPD upregulated their P2X7 receptor expression compared with control subjects (Lommatzsch et al., 2010). In line with the higher P2X7 receptor expression on macrophages from COPD patients, P2X7 stimulation triggered higher production of proinflammatory cytokines and matrix metalloproteinase 9 by macrophages of patients with COPD compared with macrophages from control subjects (Lommatzsch et al., 2010). In contrast, P2X7 receptor stimulation on macrophages induced a more pronounced suppression of tissue inhibitor of matrix metalloproteinase-1 release in patients with COPD (Lommatzsch et al., 2010). Since proinflammatory cytokines and matrix metalloproteinase-9 contribute to lung tissue destruction while tissue inhibitor of matrix metalloproteinase-1 prevents it (Daheshia, 2005; Demedts et al., 2005; Churg et al., 2012), the P2X7 receptor modulation of proinflammatory cytokines and extracellular matrix regulating enzymes appear to be harmful in COPD. Blood neutrophils from COPD patients had upregulated P2Y2 receptor expression as well as a marked increase in P2Y2-mediated migration and elastase release compared with neutrophils from healthy subjects (Lommatzsch et al., 2010). Since elastase is important in extracellular matrix degradation (Churg et al., 2012; Bidan et al., 2015), this indicates that P2Y2 receptors on neutrophils may contribute to lung tissue breakdown.

Murine studies have corroborated the proinflammatory and destructive role of ATP and P2 receptors in COPD. Mice exposed to cigarette smoke had increased P2X7 receptors primarily in airway macrophages and neutrophils and in lung tissue (Lucattelli et al., 2011). Both pharmacological blockade of P2X7 with KN62 and experiments performed using P2X7 receptor KO mice revealed a prominent role of this receptor subtype in
mediating the pro-inflammatory effects of ATP on cigarette smoke-induced lung inflammation and injury (Lucattelli et al., 2011). Similar to observations in human patients (Lommatsch et al., 2010), P2Y2 receptors contributed to neutrophil migration in mice (Cicko et al., 2010). In addition, as P2Y2 receptor-deficient mice had reduced pulmonary inflammation following cigarette smoke exposure, the authors concluded that P2Y2 receptors may be involved in the pathogenesis of cigarette smoke-induced COPD (Cicko et al., 2010).

Elevated levels of adenosine were detected in the airway lining fluid of patients with COPD compared with normal controls (Polosa, 2002). Using mass spectrometric analysis of exhaled breath condensate, Esther et al. (2011) evaluated AMP and adenosine concentrations on airway surfaces in COPD patients in comparison with healthy smokers and nonsmokers. The results demonstrated elevated airway AMP and adenosine levels in subjects with COPD, which were correlated with several markers of disease severity (Esther et al., 2011).

Adenosine receptors were also found to be altered in COPD patients. That is, in an early study, COPD subjects had decreased affinity but increased density and mRNA expression of A2A and A3 receptors in peripheral lung tissue (Varani et al., 2006). To explain these alterations, the authors speculated that increased adenosine in COPD patients might desensitize A2A and A3 receptors in the lung, which might result in the compensatory upregulation of these receptors. A1 receptor affinity decreased and density increased, but no changes in mRNA expression levels were noted. The affinity of A2B receptors was not altered, but A2B receptor density and mRNA expression decreased in peripheral lung tissue of patients with COPD compared with the control group. These inconsistencies with regard to A1 and A2B receptor affinity, density, and mRNA expression in whole lung can potentially be ascribed to the differential expression of A1 and A2B receptor expression on the various cell types in the lung (Varani et al., 2006). For example, while A2B receptors were found to be downregulated on macrophages (Varani et al., 2010), A2B receptor expression was heightened on pulmonary artery smooth muscle cells of COPD patients (Karmouty-Quintana et al., 2013). The clinical significance of these changes in adenosine receptor subtype expression and function in patients with COPD is unclear at this point. Varani et al. (2006) detected a significant correlation between the density and affinity of A2A, A2B, and A3 and the forced expiratory volume in one second/forced vital capacity ratio, an established index of airflow obstruction. In a mouse model, A2A receptor stimulation with CGS21680 was unable to suppress cigarette smoke-induced inflammation (Bonneau et al., 2006; Mantell et al., 2008). Although these findings hint that adenosine receptors may modulate the course of COPD, further studies will be necessary to precisely delineate the role of the various adenosine receptors in regulating the course of COPD in patients.

Aliagas et al. (2018) found decreased CD39 gene and protein expression as well as activity in the lungs of COPD patients in comparison with controls. This decrease in CD39 correlated with higher systemic inflammation and intimal thickening of muscular pulmonary arteries in the COPD group (Aliagas et al., 2018). Immunohistochemical analysis showed that CD39 was downregulated mainly in lung parenchyma, in epithelial bronchial cells, and in the endothelial cells of pulmonary muscular arteries (Aliagas et al., 2018). In contrast, another study demonstrated that CD39 expression and activity were higher in sputa and BAL cells of COPD patients compared with controls (Lazar et al., 2016). Experiments performed on mice chronically exposed to cigarette smoke confirmed increased CD39 in lung tissue (Lazar et al., 2016). In addition, the same study showed that CD39-deficient mice displayed a worsening of lung inflammation induced by both acute and chronic cigarette smoke exposure, which was partially rescued by the administration of apyrase, a CD39 analog. This indicates that CD39 is protective in COPD (Lazar et al., 2016). Another recent study reported increased CD39 expression on peripheral T cells in patients with acute exacerbations of COPD compared with both COPD patients without exacerbations and healthy controls.

CD73 expression was found to be upregulated and ADA downregulated in lung tissue of patients with COPD (Zhou et al., 2010), indicating that the lung environment in COPD may favor the accumulation of adenosine.

Of note, it will be important to address the role of the purinergic machinery in regulating COPD in more detail. In particular, it would be of interest to investigate how and to what extent the purinergic pathway is involved in the extensive immune dysfunction observed in COPD patients, with particular regard for the role of purines in shaping CD4+PD-1+ exhausted effector T cells, and myeloid-derived suppressor cells, which are involved in COPD pathophysiology.

**J. Asthma**

Asthma is a chronic inflammatory disorder of the airways (Colucci et al., 2007). Clinically, asthma is characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and cough. Reversible airway obstruction, mucus overproduction, and bronchial hyperresponsiveness triggered by specific and nonspecific stimuli, such as allergens, chemical irritants, cold air, and exercise underlie the symptoms of asthma (Colucci et al., 2007). Mast cells, eosinophils, Th2 lymphocytes, group 2 innate lymphoid cell types, IgE-producing B lymphocytes, DCs, macrophages, and eosinophils are the key players of the type 2 immune response driving inflammation in asthma (Barnes, 2018). The type 2 immune response is driven primarily by the
with the AZ9056, a specific P2X7 receptor-antagonist and receptors also promote asthma in mice. Both mice treated with asthma (Idzko et al., 2007). P2X1 receptor-mediated stromal lymphopoietin, IL-25, and IL-33.

well as by the damage-associated cytokines thymic "siveness in a murine OVA asthma model. P2X4 recep-

Th2 cytokine production, and bronchial hyperrespon-

sions on DCs were implicated as having a central role in asthma (Muller et al., 2011). Adoptive transfer studies showed that both the P2X4 receptor antagonist 5-BDBD (5-(3-bromophenyl)-1,3-dihy dro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one) and P2X4 deficiency alleviated the proinflammatory effects of ATP in asthma. They showed that the P2X4 receptor may be one of the mediators of asthma compared with healthy controls. As a result, asthmatic eosinophils have increased chemotactic responses and reactive oxygen metabolite production in response to ATP compared with healthy individuals (Muller et al., 2010). A recent genome-wide association study identified P2Y13 and P2Y14 as genes associated with asthma risk (Ferreira et al., 2017). Bronchial provocation test with nebulized AMP is an objective test for airway hyperresponsiveness that is clinically useful to aid in the diagnosis of asthma. A study by Basoglu et al. (2005) compared the effect of ATP with that of AMP on airway hyperresponsiveness in patients with asthma. The study demonstrated that ATP was a more potent and efficacious inducer of airway hyperresponsiveness in asthmatic patients than AMP. As ATP but not AMP activates P2 receptors, this finding indicates that P2 receptors may contribute to the symptoms of asthma in humans (Basoglu et al., 2005).

Preclinical studies also point to a pro-inflammatory role of extracellular ATP and P2 receptors in asthma. Neutralization of ATP using apyrase or pharmacologi- cal P2 receptor antagonism with pyridoxalphosphate-6-azophenyl-2', 4'-disulfonic acid (PPADS) or oxATP decreased inflammation in an ovalbumin (OVA) model of asthma (Idzko et al., 2007). In contrast, exogenously added ATP promoted sensitization to inhaled OVA in mice (Idzko et al., 2007). Zech et al. (2016) demonstrated that the P2X7 receptor may be one of the mediators of the proinflammatory effects of ATP in asthma. They showed that both the P2X4 receptor antagonist 5-BDBD (5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one) and P2X4 deficiency alleviated BAL fluid eosinophilia, peribronchial inflammation, Th2 cytokine production, and bronchial hyperresponsiveness in a murine OVA asthma model. P2X4 receptors on DCs were implicated as having a central role in promoting asthma, as adoptive transfer of P2X4 receptor-deficient DCs attenuated the Th2 response and inflammation in OVA-sensitized mice (Zech et al., 2016). P2X7 receptors also promote asthma in mice. Both mice treated with the AZ9056, a specific P2X7 receptor-antagonist and P2X7-deficient mice had reduced features of lung inflammation, such as airway eosinophilia, goblet cell hyperplasia, and bronchial hyperresponsiveness to methacholine in both the OVA model and a house dust mite model of asthma (Muller et al., 2011). Adoptive transfer studies incriminated P2X7 receptor signaling on DCs as a major proinflammatory factor in asthma (Muller et al., 2011).

P2Y1 receptors were recently shown to be involved in regulating allergic inflammation. Treatment of OVA-sensitized mice with the selective and competitive P2Y1 antagonist 2'-deoxy-N'-methyladenosine 3',5'-bisphosphate (MRS2179) or (1R*,2S*)-4-[2-iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonoxy) bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester (MRS2500) inhibited leukocyte recruitment to the lung (Amison et al., 2015). Since platelet depletion followed by reinfusion of platelets preincubated with MRS2500 versus vehicle-preincubated platelets resulted in decreased inflammation, the authors concluded that P2Y1 receptors on platelets are important for mediating the proinflammatory effects of P2Y1 receptors. P2Y2 receptors are also proinflammatory in asthma.

In one study, P2Y2 receptor-deficient mice showed decreased inflammation, decreased IgE levels, decreased VCAM expression on endothelial cells, and defective eosinophil infiltration in OVA-induced asthma (Vanderstocken et al., 2010). In another study, P2Y2 receptor-deficient mice exhibited reduced allergic inflammation, which was explained by defective inflammatory cell migration into the lung and a reduced Th2 response in lymph nodes (Muller et al., 2010). One study showed that P2Y12 receptors may also contribute to asthma by serving as receptors for LTE4, a major proinflammatory mediator of asthma (Paruchuri et al., 2009). However, a subsequent study questioned the P2Y12 agonistic role of LTE4 (Foster et al., 2013).

Adenosine receptors have long been implicated in asthma (Polosa and Blackburn, 2009). Theophylline, a competitive nonselective phosphodiesterase inhibitor and also a nonselective adenosine receptor antagonist, has been used to treat asthma for a century (Barnes, 2013). Adenosine concentrations are increased in exhaled breath condensate (Huszar et al., 2002) or BAL fluid (Driver et al., 1993) of patients with asthma compared with healthy subjects. Inhaled adenosine is a potent bronchoconstric- tor in human asthma patients but not in healthy subjects (Cushley et al., 1983). These results indicate that adenosine receptors contribute to asthma development and symptoms.

A1 receptor expression is increased in bronchial biopsies from patients with asthma versus healthy subjects (Brown et al., 2008b). A2A receptors are expressed at higher levels on peripheral blood mononuclear cells of patients with mild-to-moderate asthma than healthy patients or patients with severe asthma (Wang et al., 2018a). In sputum, asthma patients had a lower percentage of neutrophils expressing A2B receptors than healthy subjects (Versluis et al., 2008). A3 receptor transcript abundance was greater in lung tissue of asthmatic than in healthy patients (Walker et al., 1997).

Preclinical evidence supports the notion that adenosine signaling participates in the regulation of pulmonary inflammation and damage in asthma (Sun et al., 2006;
Mohsenin et al., 2007). Mice lacking ADA and therefore having elevated extracellular adenosine levels develop pulmonary inflammation with features typically observed in patients suffering from asthma, such as an increase in alveolar macrophages, airway remodeling, increased mucin production, angiogenesis, and alveolar airway enlargement (Blackburn et al., 2000). Lung-specific IL-13 overexpression in mice produced eosinophil-, lymphocyte-, and macrophage-rich inflammation, alveolar enlargement, mucus metaplasia, and airway hyperresponsiveness on methacholine challenge (Zhu et al., 1999). Blackburn et al. (2003) demonstrated that extra-cellular adenosine was elevated in these mice and ADA therapy prevented the asthmatic phenotype, indicating that adenosine mediated the proinflammatory effects of IL-13. By crossbreeding adenosine receptor-deficient mice onto the ADA-deficient background, Blackburn and coworkers demonstrated that A1, A2A, and A2B receptors protected against lung inflammation, whereas A3 receptors contributed to it (Young et al., 2004; Sun et al., 2005; Mohsenin et al., 2007; Zhou et al., 2009).

The protective role of A2B receptors, however, was not confirmed using a pharmacological approach in ADA-deficient mice, as pharmacological blockade of A2B receptors with CVT-6883 starting on postnatal day 24 reduced the number of immune cells in the BAL fluid, decreased the production of pro-inflammatory cytokines and chemokines, and attenuated pulmonary fibrosis (Sun et al., 2006). The reason for the discrepant results of the knockout and pharmacological studies is unclear at this point. One possible explanation is that A2B receptors affect asthma in a stage dependent manner, where A2B receptor inactivation from birth may be pro-inflammatory, whereas A2B receptor blockade initiated after birth may be protective.

Allergen sensitization models have also been helpful in delineating the role of adenosine receptors in asthma. In a ragweed model, A1 receptor-deficient mice exhibited decreased IL-5 and ICAM-1 expression and decreased airway hyperresponsiveness, indicating that A1 receptors are proinflammatory in this model (Ponnoth et al., 2010). Pharmacological studies using a selective A1 antagonist also pointed to a proinflammatory role of A1 receptors in a house dust mite asthma model in rabbits (Obiefuna et al., 2005). A2A receptor-deficient mice challenged with ragweed had increased inflammation, NF-κB activation, and airway reactivity to methacholine, indicating that A2A receptors are protective in this model of asthma (Nadeem et al., 2007). Pharmacological stimulation of A2A receptors is in general anti-inflammatory, although the protective effects are variable. After repeated ovalbumin challenges in mice, intranasally administered CGS21680 inhibited BAL fluid inflammatory cell influx but had no effect on OVA-induced bronchoconstriction and airway hyperactivity (Bonneau et al., 2006). In another murine OVA model, CGS21680 upregulated the Treg transcription factor FoxP3 and the Treg-derived cytokine TGF-β, decreased the Th-17-related transcription factor RORγT and IL-17, and improved lung function (Wang et al., 2018a). The anti-inflammatory effects of A2A agonism in mice were not borne out in a human clinical trial, as the selective A2A agonist GW328267X failed to affect the inflammatory response and airway hyperresponsiveness in patients with asthma (Luijk et al., 2008).

Genetic ablation of A2B receptors in mice attenuated OVA-induced chronic pulmonary inflammation, IL-4 and TGF-β production, and pulmonary inflammation and injury (Zaynagetdinov et al., 2010), indicating that A2B receptors contribute to the pathophysiology of asthma. Similarly, both global and myeloid A2B receptor deficiency decreased pulmonary inflammation, Th2 cytokine production, and chemokine level in a cockroach-allergen murine model (Belikoff et al., 2012). Pharmacological studies with a selective A2B receptor antagonist confirmed the proinflammatory role of A2B receptors in murine asthma (Basu et al., 2017a, b). Using both A3 receptor-deficient mice and treatment with IB-IMECA, Young et al. (2006) demonstrated that A3 receptors contribute to airway mucin secretion after OVA challenge of mice. However, pulmonary inflammation and function were not determined in this study.

The purinergic enzyme machinery also influences the course of asthma. Asthma patients have decreased proportions of CD39+ Tregs among all Tregs compared with healthy individuals (Wang et al., 2013). CD39 mRNA levels in both CD4+ T cells (Wang et al., 2013) and peripheral blood mononuclear cells are decreased in asthma patients versus healthy subjects (Wang et al., 2014a). This suggests that insufficient CD39-mediated immune suppression may contribute to the progression of asthma. Surprisingly, mice lacking CD39 displayed a milder asthma phenotype than wild-type mice when tested in both the OVA and house dust mite models (Idzko et al., 2013). This decrease in asthma severity in the CD39-deficient mice was due to aberrant migration of DCs with a consequent limitation of the capacity of these cells to prime Th2 responses (Idzko et al., 2013).

Similar to CD39, the proportions of CD73+ Tregs among all Tregs, as well as CD73 mRNA expression in CD4+ T cells was lower in asthmatic patients than in healthy subjects (Wang et al., 2013). The role of CD73 in regulating asthma remains to be determined.

K. Inflammatory Bowel Diseases

IBDs, such as Crohn’s disease and ulcerative colitis, are chronic relapsing disorders of the gastrointestinal tract. They are characterized by intestinal inflammation and epithelial injury (Neurath, 2014). Major symptoms include abdominal pain, diarrhea, bloody stool, malabsorption, and weight loss (Huang and Chen, 2016). Patients with IBD often suffer from other autoimmune diseases as well, such as primary sclerosing cholangitis, psoriasis, and ankylosing spondylitis.

370 Antonioli et al.
(Huang and Chen, 2016). Deregulated immune responses in the intestinal mucosa are critical factors that precipitate the onset of IBDs (Neurath, 2014). IBD patients have both altered T cell homeostasis and antigen-presenting cell dysfunction (Neurath, 2014). Th1 and Th17 cells and other IL-17 and IFN-γ-producing cells are major pathogenic contributors to the intestinal inflammatory manifestations of IBD (Neurath, 2014). IL-12 and IL-23, produced predominantly by DCs and macrophages, are major drivers of the development and activation of Th1 and Th17 cells, respectively (Neurath, 2014). The intestinal mucosal epithelium is also involved in the pathophysiology of IBD. Its barrier function is compromised, leading to increased permeability to noxious intraluminal agents, such as bacteria. Bacteria crossing the intestinal barrier activate the mucosal immune system and drive inflammation (Turner, 2009; Cazenzi et al., 2013; Martini et al., 2017).

Purinergic pathways are important for the maintenance of intestinal homeostasis by shaping the communication among luminal bacteria, epithelial cells, and the enteric immune system. High levels of extracellular ATP are commonly observed in the presence of intestinal inflammation (Wan et al., 2016; Lanis et al., 2017). ATP is released from damaged intestinal epithelial cells (Kurashima et al., 2015) as well as from immune/inflammatory cells, including neutrophils (Dosch et al., 2018) and macrophages (Sakaki et al., 2013). Another source of extracellular ATP is the intestinal commensal flora (Atarashi et al., 2008; Inami et al., 2018). ATP released from intestinal commensal bacteria participates in enteric homeostatic regulatory mechanisms by inducing the differentiation of naturally occurring Th17 cells, which control bacterial and fungal infections at the mucosal surface (Atarashi et al., 2008). ATP released from commensal bacteria is also important for the maintenance of host-microbiota mutualism. That is, ATP, through P2X1 receptors, promotes regeneration of T follicular helper cells, limits the secretory IgA response to commensal bacteria in the small intestine, thereby leading to the selection of a beneficial commensal microbial community for the host (Proietti et al., 2014; Perruzza et al., 2017).

P2X7 receptors are upregulated in both the intestinal epithelial layer and the lamina propria of patients with both Crohn’s disease and ulcerative colitis (Neves et al., 2014). In the inflamed lamina propria of patients with IBD, P2X7 receptors colocalize mainly with DCs and to a lesser extent with macrophages and T cells (Neves et al., 2014).

Studies performed in a T cell-mediated chronic colitis mouse model highlighted the relevance of P2X7 receptors in stimulating T-cell conversion into Th17 cells (Schenk et al., 2008). That is, repeated administration of oxATP, a P2X7 antagonist, mitigated the intestinal inflammatory process, promoting the cell-autonomous conversion of naive CD4+ T cells into Treg after TCR stimulation (Schenk et al., 2008, 2011). In addition, adoptive transfer of P2X7 receptor-deficient Treg but not wild-type Treg protected lymphopenic CD3ε−/− mice from colitis induced by adoptive transfer of naive CD45.1+CD4+ T cells (Schenk et al., 2011).

Rats with trinitrobenzene sulfonic (TNBS) acid-induced colitis treated with the P2X7 receptor antagonists AT400003 [1-N-[[cyano(5-quinolylamino)amino]-2,2-dimethylpropyl]-2(3,4-dimethoxyphenyl)acetamide] before colitis induction had improved disease scores and decreased inflammation compared with rats treated with vehicle (Marques et al., 2014). P2X7 receptor-deficient mice were less susceptible to TNBS- or dextran sulfate-sodium (DSS)-induced colitis than wild-type animals (Neves et al., 2014; Hofman et al., 2015; Figliuolo et al., 2017). The beneficial effect of P2X7 receptor deficiency in these studies was associated with decreased production of inflammatory cytokines, decreased NF-κB activation and Treg accumulation (Neves et al., 2014; Hofman et al., 2015; Figliuolo et al., 2017). A study using mice with TNBS-induced colitis demonstrated a critical role of P2X7 receptors on mast cells in the development of colitis, as mast cell-deficient mice reconstituted with P2X7-knockout mast cells had decreased intestinal inflammation compared with mice reconstituted with wild-type mast cells (Kurashima et al., 2012). Clinically, a marked increase in P2X7+ mast cell numbers was observed at sites of inflammation in Crohn’s disease patients (Kurashima et al., 2012). Interestingly, despite decreased inflammation, P2X7 receptor-deficient mice exhibited increased tumor incidence in a model of colitis-associated cancer (Hofman et al., 2015). The increase in tumor formation was secondary to increased intestinal epithelial proliferation, decreased apoptosis, and increased production of TGFβ1. Although most of these studies support a proinflammatory role for P2X7 receptors in colitis, this was not borne out in a clinical study. In a placebo-controlled, multicenter, double-blind phase IIa study, Crohn’s patients treated with the P2X7 receptor antagonist AZD9056 showed no amelioration in inflammation although the Crohn’s Disease Activity Index was decreased in drug versus placebo-treated patients (Eser et al., 2015).

P2X3 receptors were upregulated in patients with IBD (Yiangou et al., 2001). P2X3 receptors were only detected in neurons of the myenteric and submucosal plexuses. The authors hypothesized that P2X3 receptors may be involved in pain and dysmotility in IBD.

P2Y2 receptors are increased in colonic tissues of IBD patients (Grbic et al., 2012). In addition, both TNF-α and IFN-γ upregulated P2Y2 receptors in the intestinal epithelium (Grbic et al., 2008). Stimulation of P2Y2 receptors with the agonist 2-thiouridine-5′-triphosphate promoted recovery from colitis in DSS-treated mice, which was mostly due to increased regeneration of the intestinal epithelium (Degagne et al., 2013). P2Y6 receptors were shown to be upregulated on T cells...
infiltrating the colon of patients with active IBD (Somers et al., 1998). Both genetic and pharmacological blockade of P2Y12 receptors ameliorated TNBS-induced colitis in mice (Qin et al., 2017), indicating that P2Y12 receptors may be targets for intervention in human IBD.

\[ \text{A2A receptor mRNA expression in colonic mucosa obtained from Crohn’s patients with active disease was found to be enhanced, while no changes were detected in ulcerative colitis patients (Rybaczky et al., 2009).} \]

In contrast, in a recent study, Tian et al. (2016) demonstrated reduced expression of A2A receptor mRNA and protein in sigmoid colonic mucosa obtained from active ulcerative colitis patients compared with normal controls. Of note, A2A protein expression was inversely correlated with the expression of miR-16 (Tian et al., 2016). Results obtained using both in siro data as well as functional studies showed that miR-16 targeted the 3’-untranslated region of A2A receptor mRNA, resulting in inhibition of A2A receptor expression (Tian et al., 2016). Preclinical studies revealed a critical role of A2A receptors in controlling the function T cells that regulate colitis. In an early study using a colitis model in which adoptive transfer of pathogenic CD45RB\(^{bigh}\)Th cells into severe combined immunodeficient mice causes colitis, it was found that co-transfer of CD45RB\(^{low}\) or CD25\(^{+}\)Th cells lacking A2A receptors failed to prevent disease, whereas wild-type CD45RB\(^{low}\) or CD25\(^{+}\)Th cells did prevent disease (Naganuma et al., 2006). In a more recent pharmacological study, systemically administered inosine was protective against TNBS-induced colitis, and the protective effects were shown to be mediated by A2A receptors (Rahimian et al., 2010). Systemic administration of the selective A2A receptor agonist CGS21680 was, however, not protective in mice with DSS-induced colitis (Selmeczy et al., 2007). In contrast, oral administration of the poorly absorbed A2A receptor agonist PSB-0777 was anti-inflammatory and protective in a rat model of oxazolone-induced colitis (Antonioli et al., 2010). Thus, the systemic effects of A2A receptor stimulation may offset its local protective effects. Of note, A2A receptors have also been shown to control the neuroplastic changes occurring in the inflamed gut (Antonioli et al., 2006). Thus, it was proposed that A2A agonists may be useful to stem enteric motor dysfunctions, which are typically observed in IBD patients (Antonioli et al., 2006, 2011).

The gut expresses high levels of A2B receptors with intestinal epithelial cells as major contributors (Hasko et al., 2009; Colgan et al., 2013). A marked upregulation of A2B receptor expression was observed in the intestinal mucosa during both human and murine colitis, and A2B receptor expression was highest in intestinal epithelial cells (Kolachala et al., 2005). In this context, A2B receptors have been shown to modulate several epithelial cell functions, such as secretory activity, barrier function, and interaction with bacteria, which are all important factors in IBD (Kolachala et al., 2005). A2B receptors are also expressed on endothelial cells and macrophages (Yang et al., 2006). Early studies by one group using both genetic knockout mice and pharmacological blockade indicated that A2B receptors contribute to the severity of symptoms and inflammation of colitis in mice (Kolachala et al., 2008a,b). Subsequently, another group found that both general A2B receptor knockout and pharmacological blockade augmented the course of colitis and suppressed inflammation, indicating a protective role for A2B receptors (Frick et al., 2009). Using intestinal epithelial cell-specific A2B receptor deficient mice, the same group then went on to show that A2B receptors on epithelial cells are important for protection against colitis, suppression of inflammation, and gut barrier function (Aherne et al., 2015).

Potential explanations for why the two groups found opposing roles for A2B receptors include differences in the colitis protocols, differences in murine strains with genetic deletion of the A2B receptors, and differences in housing conditions, including potential differences in the bacterial flora of the mice (Frick et al., 2009).

Decreased expression of A3 receptors was reported in colorectal mucosa from patients with ulcerative colitis (Rybaczky et al., 2009; Wu et al., 2017) and in animal models of intestinal inflammation (Rybaczky et al., 2009; Ren et al., 2011). In contrast, A3 receptor was overexpressed in peripheral blood mononuclear cells of Crohn’s patients (Ochaion et al., 2009). IB-MECA treatment of mice with DSS-induced colitis and IL-10 deficiency-induced colitis (Mabley et al., 2003) or rats with TNBS-induced colitis prevented the clinical symptoms and histologic signs of inflammation and suppressed inflammation (Guzman et al., 2006). Counterintuitively, A3 receptor-deficient mice were protected against DSS-induced colitis (Ren et al., 2011). Such apparent discrepancies can potentially be explained by the heterogeneous experimental conditions used in the above-mentioned studies. For example, genetic deletion of A3 adenosine receptors may cause compensatory upregulation of other receptor subtypes, i.e., the A2A, which would then exert protective effects in intestinal inflammation (Naganuma et al., 2006). Alternatively, it is possible that the differential results may be due to differences in the bacterial flora among the various studies, as the bacterial flora is an important factor in colitis (Guarner and Malagelada, 2003).

The CD39/CD73 axis has emerged as a potential pharmacological target in IBD. In humans with IBD, CD39 expression on T\(_{\text{regs}}\) was lower compared with healthy patients (Gibson et al., 2015). CD39 expression on T\(_{\text{regs}}\) increased after treatment with the anti-TNF-\(\alpha\) antibody infliximab (Gibson et al., 2015). Bai et al. (2014) described a human Th17 subpopulation with suppressor activity, which expresses high levels of CD39 and consequently produces extracellular adenosine (Bai et al., 2014). These uniquely suppressive CD39\(^+\)Th17 cells are decreased in patients with IBD (Bai et al., 2014). CD39\(^+\)CD8\(^+\) T cells were significantly increased in
peripheral blood and lamina propria of patients with active Crohn’s disease compared with healthy donors (Bai et al., 2015). Similar to CD39+ Th17 cells, CD39+CD8+ T cells exert immunosuppressive effects through the generation of extracellular adenosine (Bai et al., 2015). A single nucleotide polymorphism tagging low levels of CD39 expression was associated with increased susceptibility to Crohn’s disease in a case-control cohort comprising 1748 Crohn’s patients and 2936 controls (Friedman et al., 2009). Overall, these results suggest a protective role for CD39 in human patients with IBD.

The role of CD39 in mouse models is controversial. In an early study, CD39-deficient mice exhibited increased susceptibility to DSS-induced colitis, which was rescued by exogenously introduced apyrase (Friedman et al., 2009). In addition, unconjugated bilirubin protected against DSS-induced colitis through upregulating CD39 on Th17 cells (Longhi et al., 2017). In another study, employing mice with TNBS-induced colitis CD39 deficiency was protective (Kunzli et al., 2011). In the same study, the severity of oxazolone-induced colitis was similar in CD39 deficient and wild-type mice (Kunzli et al., 2011). The authors posited that one explanation for the different observations in the two models is that while the TNBS model exhibits clinicopathological findings that are more similar to Crohn’s disease, oxazolone-induced colitis has features similar to ulcerative colitis (Boirivant et al., 1998). Clearly, further studies using mice with cell-specific and temporal targeting of CD39 will be necessary to resolve the role of CD39 in colitis.

In the intestinal mucosa, CD73 appears to have a critical role in maintaining homeostasis (Svynestvedt et al., 2002; Colgan et al., 2006; Louis et al., 2008; Sotnikov and Louis, 2010). In patients with IBD, increased numbers of CD73+CD4+ T cells in the periphery and lamina propria were noted during active inflammation, which returned to baseline levels following anti-TNF treatment (Doherty et al., 2012). Similar to observations with CD39 noted above (Bai et al., 2014), the CD73+CD4+ T-cell population in patients with active IBD were enriched with cells with a T-helper type 17 phenotype (Doherty et al., 2012).

There is a marked induction of colonic mucosal CD73 expression in response to TNBS-induced colitis in mice (Louis et al., 2008). CD73-deficient mice with TNBS-induced colitis showed a worsening of clinical course and inflammation severity (Louis et al., 2008). In addition, in mice with TNBS-induced colitis the selective CD73 inhibitor α,β-methylene ADP increased colitis severity (Louis et al., 2008). Since IFN-αA was downregulated in colitis and exogenous IFN-αA reversed the deleterious CD73 phenotype, the authors argued that CD73 protects against colitis through inducing IFN-αA. Similar to results with the TNBS model of colitis, CD73 was also protective in the DSS model (Bynoe et al., 2012). When pathogenic CD4+ CD45RBhigh cells were adoptively transferred to Rag deficient mice, cotransfer of wild-type Treg was as protective as cotransfer of CD73-deficient Treg (Bynoe et al., 2012). Thus it was concluded that CD73 expression on Treg was not needed for protection.

Several studies have been performed to evaluate the role of ADA in the pathophysiology of IBDs (Antonioli et al., 2012). Serum obtained from Crohn’s patients during active disease had increased total ADA and ADA2 levels compared with both patients in remission and healthy subjects (Maor et al., 2011). Increased expression of ADA was also detected in murine models of intestinal inflammation (Antonioli et al., 2010a, 2014). In addition, pharmacological blockade of ADA ameliorated IBD in rodent models (Antonioli et al., 2007, 2010a; Brown et al., 2008a; La Motta et al., 2009), Thus ADA may serve as both a disease marker and therapeutic target in IBD.

In colonic tissue obtained from IBD patients, ENT1, ENT2, and CNT2 mRNA levels were higher in comparison with control specimens (Wojtal et al., 2009) (Fig. 4). A recent study by Aherne et al. (2018) demonstrated that the administration of dipyridamole, a pharmacologic blocker of ENT 1 and ENT2, protected mice against DSS-induced colitis. Of note, the genetic loss of Ent1 failed to alter the outcome of DSS colitis in mice, whereas animals with global or mucosal Ent2 deletion were protected against intestinal inflammation, suggesting a detrimental role for ENT2 during experimental colitis (Aherne et al., 2018). Mechanistic studies demonstrated that ENT2 inhibition or deficiency increased extracellular adenosine levels, which were protective through A2BR receptor activation (Aherne et al., 2018).

At present, several lines of preclinical evidence support the possibility of encouraging beneficial effects resulting from the pharmacological modulation of purinergic pathways in bowel inflammation. In particular, A2AR and A3 receptor agonists were effective in curbing several digestive dysfunctions typically associated with IBDs, such as visceral pain, diarrhea, ischemia, and functional disorders. However, despite these promising results, several issues pertaining to the regulation of digestive functions by the purinergic system remain unexplored and deserve further investigations.

V. Future Directions

Based on evidence reviewed here, we propose that IMIDs share molecular alterations of some of the key elements of the purinergic machinery. Some of these alterations are shared across a wide variety of IMIDs and include downregulation of A2AR receptors on effector T cells, upregulation of A2AR and A3 receptors on PBMCs, upregulation of P2X7 receptors on effector T cells, increased ADA levels, and reduced activity of the CD39/CD73 enzyme axis on the surface of Treg (Fig. 5). Thus it is possible that targeting these key purinergic nodes may be a worthy strategy for drug development to
manage patients with various IMIDs. One caveat is that in some cases, the available data regarding the role of the purinergic system in some aspects of IMID pathophysiology are based only on individual studies, and in this case it is not possible to have consolidated evidence or draw substantial conclusions. In addition, it is necessary to point out that there are also competing and sometimes contradictory actions of the role of the purinergic system in IMIDs. For example, conflicting evidence has been observed regarding T_{eff} cells. In particular, increases in A_{2A} receptor expression were observed in T_{eff} cells from SLE and uveitis patients, whereas A_{2A} receptor expression appears reduced in myasthenia gravis, psoriasis, and IBD (Fig. 5). In addition, CD73 expression on T_{eff} cells was increased in IBD and reduced in uveitis and SLE (Fig. 5). In some cases, increased CD73 and A_{2A} receptor expression may have compensatory anti-inflammatory functions, while in other cases they may contribute to disease pathophysiology and progression.

Although many next-generation ligands acting on the purinergic system are both reasonably selective in vitro and display encouraging beneficial effects in in vivo preclinical models, once thrown into the clinical arena their efficacy has turned out to be less than optimal. P2X_{7} receptor antagonists are a prime example of this. When novel and safe P2X_{7} receptor antagonists that have been shown to be effective in experimental models of inflammation, such as EAE, IBDs, and rheumatoid arthritis, were tested in humans, the results of these clinical studies were disappointing [see (Keystone et al., 2012; Stock et al., 2012; Eser et al., 2015)]. Although there is no definitive explanation for this lack of pharmacological efficacy in humans, one possibility is that the inefficient targeting of P2X_{7} receptors is caused by the high variation of P2X_{7} function among individuals, which is due to the numerous single nucleotide polymorphisms resulting in either loss- or gain-of-function (Sluyter and Stokes, 2011). For this reason, it will be of importance to determine the relative effectiveness of P2X_{7} therapeutics in relation to P2X_{7} isoforms and polymorphic variants.

A novel theme in purinergic receptor research is receptor heteromers and coexpression. Indeed, heteromerization (the direct interaction between at least two different functional receptors forming a complex with...
specific biochemical and functional properties different from those of its component receptor units (Albizu et al., 2010) is emerging as an important process involved in the specialization of receptor function (Rozenfeld and Devi, 2010). This may be due to conformational changes in the heteromerized receptors within the receptor-receptor interface at the plane of the membrane bilayer or G-protein-mediated cooperativity in the plane of the membrane (Franco et al., 2008). Of note, the presence of receptor heteromers is reported in select tissues, and, in some cases, the heteromerization has been described to be involved in pathophysiological events (Franco et al., 2008). In this regard, P2X7 and P2X4 are widely coexpressed, particularly in secretory epithelial cells and immune and inflammatory cells, and together participate in the regulation of inflammation and nociception (Schneider et al., 2017). There is also some evidence that P2X4 and P2X7 can associate to form heteromeric receptors in some cell types under certain conditions (Guo et al., 2007). As these heteromers may have novel pharmacological profiles that differ from those of the constituting homomers, new drugs targeting the heteromers may have fewer side effects than drugs targeting the widely expressed homomers. The identification of crystal structures of P2X3, P2Y2, or P2Y6 receptors (emerging as interesting molecular targets involved in shaping immune cell activity) may also help in better understanding the receptor function, fundamental signaling, thus paving the way toward the development of novel drugs potentially useful to counteract the inflammatory process. However, it is worth noting that there is still a long way to go in this field, since there is a paucity of studies on whether a given heteromer may form and become functional in the course of IMIDs.

In addition, another relevant aspect of purinergic pharmacology of IMIDs that deserves further study is the evaluation of how and to what extent drugs acting on purinergic signaling may have synergistic effects when administered together with other immunomodulatory agents. One study by Ochaion et al. (2006) reported a synergistic effect between methotrexate and CF101. Mechanistically, in a murine model of adjuvant-induced arthritis, methotrexate induced an increase in A3 receptor expression in inflamed tissues, thereby rendering the tissues more responsive to CF101 treatment (Ochaion et al., 2006).

In summary, given the pressing unmet medical need for novel pharmacological approaches for the management of IMIDs and the compelling data supporting the efficacy of targeting the purinergic system in preclinical...


Kim DG and Bynoe MS (2015) A2A adenosine receptor regulates the human blood-
Künzli BM, Berberat PO, Dwyer K, Deaglio S, Csizmadia E, Cowan P, d
Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden
Kim DG and Bynoe MS (2015) A2A adenosine receptor regulates the human blood-
La Motta C, Sartini S, Mugnaini L, Salerno S, Simorini F, Taliani S, Marinelli AM, Da Settimo F, Lavecchia A, Novellino E, et al. (2009) Exploiting the pyrazolo[3,4-
Deaglio S, Csizmadia E, Cowan P, d


Antonioli et al. (2016)**


Antonioli et al. (2016)**


Antonioli et al. (2016)**


